UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

þQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the quarterly period ended March 31, 2008

OR

 ̈Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ___________ to ___________

Commission File No. 1-16119



PHARMANET DEVELOPMENT GROUP, INC.

(Exact name of registrant as specified in its charter)



|                                                               |                                  
|-------------------------------------------------------------- | ---------------------------------
|                                                               |                                  
|Delaware                                                       | 59-2407464                       
|(State or other jurisdiction of
incorporation or organization) | (IRS Employer
Identification No.)



504 Carnegie Center

Princeton, NJ 08540

(Address of principal executive offices) (Zip code)

(609) 951-6800

(Registrants telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No  ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

|                           |  |                    |  |                                                                       |  |                            
|-------------------------- |  | ------------------ |  | --------------------------------------------------------------------- |  | ---------------------------
|Large accelerated filer  o |  | Accelerated filerþ |  | Non-accelerated filer  o(Do not check if a smaller reporting company) |  | Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  ̈ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

|                                         |                           
|---------------------------------------- | --------------------------
|Class                                    | Outstanding at May 5, 2008
|Common Stock, $0.001 par value per share | 19,325,934 shares         











---

INDEX

|                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|PART I  FINANCIAL INFORMATION                                                                                                                                                                                                                                                                                                                                                                                                                            
|Item 1.      Financial Statements
1
Item 2.      Managements Discussion and Analysis of Financial Condition and Results of Operations
14
Item 3.      Quantitative and Qualitative Disclosures about Market Risk
21
Item 4.      Controls and Procedures
22
PART II  OTHER INFORMATION
Item 1.      Legal Proceedings
23
Item 1A.   Risk Factors
24
Item 2.      Unregistered Sales of Equity Securities and Use of Proceeds
35
Item 6.      Exhibits
35







i





---

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)



|                                                                                                                                                                          |                |         |                   |   |        
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------- | ------- | ----------------- | - | -------
|                                                                                                                                                                          | March 31,
2008 |         | December 31,
2007
|                                                                                                                                                                          | (Unaudited)    |         |                   |  
|ASSETS                                                                                                                                                                    |                |         |                   |   |        
|Current Assets:                                                                                                                                                           |                |         |                   |   |        
|Cash and cash equivalents                                                                                                                                                 | $              | 63,926  |                   | $ | 77,548 
|Investment in marketable securities                                                                                                                                       |                |        |                   |   | 2,650  
|Accounts receivable, net                                                                                                                                                  |                | 131,087 |                   |   | 132,550
|Income taxes receivable                                                                                                                                                   |                | 1,674   |                   |   | 1,855  
|Deferred income taxes                                                                                                                                                     |                | 328     |                   |   | 298    
|Prepaid expenses                                                                                                                                                          |                | 10,714  |                   |   | 6,589  
|Other current assets                                                                                                                                                      |                | 4,938   |                   |   | 5,274  
|Assets from discontinued operations                                                                                                                                       |                |        |                   |   | 5,199  
|Total current assets                                                                                                                                                      |                | 212,667 |                   |   | 231,963
|Property and equipment, net                                                                                                                                               |                | 69,015  |                   |   | 67,506 
|Goodwill                                                                                                                                                                  |                | 266,973 |                   |   | 266,973
|Other intangible assets, net                                                                                                                                              |                | 25,852  |                   |   | 26,442 
|Deferred income taxes                                                                                                                                                     |                | 13,831  |                   |   | 14,111 
|Other assets, net                                                                                                                                                         |                | 7,862   |                   |   | 7,840  
|Total assets                                                                                                                                                              | $              | 596,200 |                   | $ | 614,835
|                                                                                                                                                                          |                |         |                   |   |        
|LIABILITIES AND STOCKHOLDERS EQUITY                                                                                                                                      |                |         |                   |   |        
|Current liabilities:                                                                                                                                                      |                |         |                   |   |        
|Accounts payable                                                                                                                                                          | $              | 9,846   |                   | $ | 13,843 
|Accrued liabilities                                                                                                                                                       |                | 32,790  |                   |   | 47,978 
|Client advances, current portion                                                                                                                                          |                | 79,763  |                   |   | 79,312 
|Income taxes payable                                                                                                                                                      |                | 942     |                   |   |       
|Capital lease obligations and notes payable, current portion                                                                                                              |                | 3,062   |                   |   | 3,562  
|Deferred income taxes                                                                                                                                                     |                | 33      |                   |   | 31     
|Other current liabilities                                                                                                                                                 |                | 332     |                   |   | 154    
|Liabilities from discontinued operations                                                                                                                                  |                |        |                   |   | 1,770  
|Total current liabilities                                                                                                                                                 |                | 126,768 |                   |   | 146,650
|Client advances                                                                                                                                                           |                | 3,047   |                   |   | 2,602  
|Deferred income taxes                                                                                                                                                     |                | 8,604   |                   |   | 8,518  
|Capital lease obligations and notes payable                                                                                                                               |                | 5,500   |                   |   | 5,634  
|2.25% Convertible senior notes payable                                                                                                                                    |                | 143,750 |                   |   | 143,750
|Other non-current liabilities                                                                                                                                             |                | 15,771  |                   |   | 15,590 
|Minority interest in joint venture                                                                                                                                        |                | 3,366   |                   |   | 2,722  
|Commitments and contingencies (Note C)                                                                                                                                    |                |         |                   |   |        
|Temporary equity:                                                                                                                                                         |                |         |                   |   |        
|Sale of unregistered common stock, subject to rescission                                                                                                                  |                | 2,169   |                   |   | 2,058  
|Stockholders equity:                                                                                                                                                     |                |         |                   |   |        
|Preferred stock, $0.10 par value, 5,000 shares authorized, none issued                                                                                                    |                |        |                   |   |       
|Common stock, $0.001 par value, 40,000 shares authorized, 19,322 shares
and 19,017 shares issued and outstanding as of March 31, 2008 and December 31, 2007, respectively |                | 19      |                   |   | 19     
|Additional paid-in capital                                                                                                                                                |                | 251,970 |                   |   | 244,017
|Retained earnings                                                                                                                                                         |                | 12,517  |                   |   | 22,616 
|Accumulated other comprehensive income                                                                                                                                    |                | 22,719  |                   |   | 20,659 
|Total stockholders equity                                                                                                                                                |                | 287,225 |                   |   | 287,311
|Total liabilities and stockholders equity                                                                                                                                | $              | 596,200 |                   | $ | 614,835



The accompanying notes are an integral part of these consolidated financial statements.

1





---

PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In thousands, except per share data)



|                                                                                      |                             |         |      |   |         |  
|------------------------------------------------------------------------------------- | --------------------------- | ------- | ---- | - | ------- | -
|                                                                                      | Three Months Ended
March 31 |        
|                                                                                      | 2008                        |         | 2007 |  
|                                                                                      |                             |         |      |   |         |  
|Net revenue:                                                                          |                             |         |      |   |         |  
|Direct revenue                                                                        | $                           | 86,800  |      | $ | 84,781  |  
|Reimbursed out-of-pocket expenses                                                     |                             | 20,644  |      |   | 22,962  |  
|Total net revenue                                                                     |                             | 107,444 |      |   | 107,743 |  
|Costs and expenses:                                                                   |                             |         |      |   |         |  
|Direct costs                                                                          |                             | 60,893  |      |   | 50,478  |  
|Reimbursable out-of-pocket expenses                                                   |                             | 20,644  |      |   | 22,962  |  
|Selling, general and administrative expenses                                          |                             | 33,391  |      |   | 25,690  |  
|Total costs and expenses                                                              |                             | 114,928 |      |   | 99,130  |  
|(Loss) earnings from continuing operations                                            |                             | (7,484  | )    |   | 8,613   |  
|Other income (expense):                                                               |                             |         |      |   |         |  
|Interest income                                                                       |                             | 548     |      |   | 542     |  
|Interest expense                                                                      |                             | (1,397  | )    |   | (1,643  | )
|Other income                                                                          |                             | 38      |      |   |        |  
|Foreign currency exchange transaction (loss) gain, net                                |                             | (387    | )    |   | 392     |  
|Total other income (expense), net                                                     |                             | (1,198  | )    |   | (709    | )
|(Loss) earnings from continuing operations before income taxes                        |                             | (8,682  | )    |   | 7,904   |  
|Income tax expense                                                                    |                             | 995     |      |   | 1,783   |  
|(Loss) earnings from continuing operations before 
minority interest in joint venture |                             | (9,677  | )    |   | 6,121   |  
|Minority interest in joint venture                                                    |                             | 422     |      |   | 129     |  
|Net (loss) earnings from continuing operations                                        |                             | (10,099 | )    |   | 5,992   |  
|Earnings from discontinued operations, net of tax                                     |                             |        |      |   | 640     |  
|Net (loss) earnings                                                                   | $                           | (10,099 | )    | $ | 6,632   |  
|                                                                                      |                             |         |      |   |         |  
|Basic (loss) earnings per share:                                                      |                             |         |      |   |         |  
|Continuing operations                                                                 | $                           | (0.53   | )    | $ | 0.32    |  
|Discontinued operations                                                               |                             |        |      |   | 0.04    |  
|Net (loss) earnings                                                                   | $                           | (0.53   | )    | $ | 0.36    |  
|Diluted (loss) earnings per share                                                     |                             |         |      |   |         |  
|Continuing operations                                                                 | $                           | (0.53   | )    | $ | 0.32    |  
|Discontinued operations                                                               |                             |        |      |   | 0.03    |  
|Net (loss) earnings                                                                   | $                           | (0.53   | )    | $ | 0.35    |  
|Weighted average common shares outstanding:                                           |                             |         |      |   |         |  
|Basic                                                                                 |                             | 19,183  |      |   | 18,630  |  
|Diluted                                                                               |                             | 19,183  |      |   | 18,858  |  





The accompanying notes are an integral part of these consolidated financial statements.

2





---

PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)



|                                                                                        |                              |         |      |   |         |  
|--------------------------------------------------------------------------------------- | ---------------------------- | ------- | ---- | - | ------- | -
|                                                                                        | Three Months Ended 
March 31 |        
|                                                                                        | 2008                         |         | 2007 |  
|Cash flows from operating activities:                                                   |                              |         |      |   |         |  
|Net (loss) earnings                                                                     | $                            | (10,099 | )    | $ | 6,632   |  
|Earnings from discontinued operations                                                   |                              |        |      |   | (640    | )
|Adjustments to reconcile net (loss) earnings to net cash 
used in operating activities: |                              |         |      |   |         |  
|Depreciation and amortization                                                           |                              | 4,387   |      |   | 3,551   |  
|Amortization and write-off of deferred debt issuance costs                              |                              | 398     |      |   | 395     |  
|(Gain) on disposal of property and equipment                                            |                              |        |      |   | (1      | )
|Minority interest                                                                       |                              | 422     |      |   | 129     |  
|Provision for doubtful accounts                                                         |                              | 154     |      |   |        |  
|Share-based compensation expense                                                        |                              | 1,436   |      |   | 1,134   |  
|Changes in assets and liabilities:                                                      |                              |         |      |   |         |  
|Accounts receivable                                                                     |                              | 4,085   |      |   | (19,489 | )
|Income taxes receivable                                                                 |                              | 1,282   |      |   | 540     |  
|Prepaid expenses and other current assets                                               |                              | (3,039  | )    |   | (543    | )
|Other assets                                                                            |                              | (216    | )    |   | (590    | )
|Accounts payable                                                                        |                              | (8,435  | )    |   | (2,207  | )
|Accrued liabilities                                                                     |                              | (11,886 | )    |   | (3,025  | )
|Client advances                                                                         |                              | (114    | )    |   | 6,986   |  
|Income taxes payable                                                                    |                              | 921     |      |   |        |  
|Other current liabilities                                                               |                              | 179     |      |   |        |  
|Deferred income taxes                                                                   |                              | (259    | )    |   | 132     |  
|Other long-term liabilities                                                             |                              | 662     |      |   | 121     |  
|Total adjustments                                                                       |                              | (10,023 | )    |   | (12,867 | )
|Net cash used in operating activities  continuing operations                           |                              | (20,122 | )    |   | (6,875  | )
|Net cash used in operating activities  discontinued operations                         |                              |        |      |   | (692    | )
|Net cash used in operating activities                                                   |                              | (20,122 | )    |   | (7,567  | )
|Cash flows from investing activities:                                                   |                              |         |      |   |         |  
|Purchase of property and equipment                                                      |                              | (1,693  | )    |   | (5,420  | )
|Proceeds from the disposal of property and equipment                                    |                              |        |      |   | 3       |  
|Purchase of intangible assets                                                           |                              | (105    | )    |   |        |  
|Net change in investment in marketable securities                                       |                              | 2,542   |      |   | (2,627  | )
|Net cash provided by (used in) investing activities  
continuing operations            |                              | 744     |      |   | (8,044  | )
|Net cash proved by investing activities  discontinued operations                       |                              |        |      |   | 1,182   |  
|Net cash provided by (used in) investing activities                                     |                              | 744     |      |   | (6,862  | )
|Cash flows from financing activities:                                                   |                              |         |      |   |         |  
|Borrowings on line of credit                                                            |                              |        |      |   | 5,000   |  
|Payments on line of credit                                                              |                              |        |      |   | (600    | )
|Payments on capital lease obligations and notes payable                                 |                              | (785    | )    |   | (709    | )
|Net proceeds from stock issued under option plans, ESPP 
and restricted stock awards    |                              | 1,514   |      |   | 600     |  
|Proceeds from sale of unregistered common stock, subject to rescission                  |                              | 1,114   |      |   | 1,003   |  
|Net cash provided by financing activities                                               |                              | 1,843   |      |   | 5,294   |  
|Net effect of exchange rate changes on cash and cash equivalents                        |                              | 3,913   |      |   | 148     |  
|Net decrease in cash and cash equivalents                                               |                              | (13,622 | )    |   | (8,987  | )
|Cash and cash equivalents at beginning of period                                        |                              | 77,548  |      |   | 45,331  |  
|Cash and cash equivalents at end of period                                              | $                            | 63,926  |      | $ | 36,344  |  



The accompanying notes are an integral part of these consolidated financial statements.

3





---

PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED)

(In thousands)



|                                                                                        |  |                              |       |      |   |      
|--------------------------------------------------------------------------------------- |  | ---------------------------- | ----- | ---- | - | -----
|                                                                                        |  | Three Months Ended 
March 31
|                                                                                        |  | 2008                         |       | 2007
|Supplemental disclosures:                                                               |  |                              |       |      |   |      
|Interest paid                                                                           |  | $                            | 1,806 |      | $ | 2,057
|Income taxes paid                                                                       |  | $                            | 1,350 |      | $ | 642  
|Income taxes recovered                                                                  |  | $                            | 43    |      | $ | 88   
|Supplemental disclosures of non-cash investing and finance activities:                  |  |                              |       |      |   |      
|Fair market value of restricted stock units granted as long-term incentive compensation |  | $                            | 5,587 |      | $ |     
|Capital lease obligations incurred                                                      |  | $                            | 320   |      | $ |     
|Settlement of class action litigation through issuance of common stock                  |  | $                            | 4,000 |      | $ |     











The accompanying notes are an integral part of these consolidated financial statements.

4





---

PHARMANET DEVELOPMENT GROUP, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE A UNAUDITED INTERIM FINANCIAL INFORMATION

The accompanying consolidated financial statements of PharmaNet Development Group, Inc. (PDGI or the Company), have not been audited. These financial statements should be read in conjunction with the consolidated financial statements and notes included in the Companys Annual Report on Form 10-K for the year ended December 31, 2007.

Use of estimates

In the opinion of management, the accompanying unaudited consolidated financial statements include all normal recurring adjustments necessary for a fair statement of financial position as of March 31, 2008, and December 31, 2007, and the results of operations and cash flows for the three months ended March 31, 2008 and 2007. Operating results for the three months ended March 31, 2008, are not necessarily indicative of the results that may be expected for the year ending December 31, 2008.

Management makes estimates and assumptions when preparing the consolidated financial statements.  These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

As of January 1, 2008, the Company, in connection with the release of its global fixed asset accounting policy, reviewed the estimated useful lives of its fixed assets. As a result, management made the determination to modify the estimate useful lives for certain fixed assets. This change increased depreciation expense by $0.3 million for the three months ended March 31, 2008. The following table sets forth the revised useful lives of property and equipment.

|                                  |                                                                                       
|--------------------------------- | --------------------------------------------------------------------------------------
|Automobiles                       | 5 years                                                                               
|Building                          | 25 years                                                                              
|Furniture and fixtures            | 7 years                                                                               
|Machinery, equipment and software | 3-10 years                                                                            
|Leasehold improvements            | Shorter of remaining life of asset or remaining term of the lease (average 3.25 years)

Significant accounting policies

The Companys significant accounting policies are described in Note A to the consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2007.  There were no significant changes to those accounting policies during the three months ended March 31, 2008.

Principles of consolidation

The accompanying unaudited consolidated financial statements include the accounts of wholly owned subsidiaries and a 49%-owned joint venture in Spain over which the Company exercises significant control. All significant intercompany balances and transactions have been eliminated in consolidation.

Recent accounting pronouncements

In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements (SFAS 157), which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  In addition, the statement establishes a framework for measuring fair value and expands disclosure about fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those years, except that FASB Staff Position 157-2 delayed the effective date of SFAS 157 until fiscal years beginning after November 18, 2008, for non-financial assets and liabilities except those that are recognized or disclosed at fair value in the financial statements on a recurring basis.  Accordingly, effective January 1, 2008, the Company adopted this limited provision of SFAS 157. The Company is currently evaluating the impact of SFAS 157 for non-financial assets and liabilities.



5





---

SFAS 157 establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Companys assumptions used to measure assets and liabilities at fair value. A financial asset or liabilitys classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The following table sets forth the assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2008.

|                           |  |                       |  |                                           |  |                                               |  |                                           
|-------------------------- |  | --------------------- |  | ----------------------------------------- |  | --------------------------------------------- |  | ------------------------------------------
|                           |  | Total Carrying 
Value |  | Quoted prices
In active markets
(Level 1) |  | Significant other
observable inputs
(Level 2) |  | Significant 
unobservable inputs
(Level 3)
|                           |  | (in thousands)       
|Forward exchange contracts |  | $ (332)               |  | $ (332)                                   |  | $                                            |  | $                                        

Derivative valuations are based on quoted prices (unadjusted) in active markets for identical assets or liabilities and are classified within Level 1 of the valuation hierarchy.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (SFAS 159). SFAS 159 provides companies with an option to report selected financial assets and liabilities at fair value. Furthermore, SFAS 159 establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. The Company adopted SFAS 159 in the interim period beginning January 1, 2008. The adoption did not have a material effect on the Companys consolidated financial position, results of operations or cash flows during the three months ended March 31, 2008.

Earnings per share

The Company computes basic earnings per share using the weighted average number of common shares outstanding during the period. The following table sets forth a reconciliation of basic and diluted earnings per share from continuing operations for the three months ended March 31, 2008 and 2007.



|                                                                        |                        |                                       |        |      |        |      |      |  | 
|----------------------------------------------------------------------- | ---------------------- | ------------------------------------- | ------ | ---- | ------ | ---- | ---- |  | 
|                                                                        |                        |                                       |        | 2008 |        |      | 2007
|                                                                        |                        | (in thousands, except per share data)
|Net (loss) earnings from continuing operations                          | $                      | (10,099)                              |        | $    | 5,992 
|Average shares of common stock outstanding for basic earnings per share |                        | 19,183                                |        |      | 18,630
|Contingently issuable shares related to:                                |                        |                                       |        |      |       
|                                                                        | Stock options          |                                       |       |      |        | 180 
|                                                                        | Restricted stock units |                                       |       |      |        | 48  
|                                                                        |                        | Total                                 |        |     |        |      | 228 
|Average shares of common stock for diluted earnings per share           |                        | 19,183                                |        |      | 18,858
|                                                                        |                        |                                       |        |      |        |      |     
|(Loss) earnings per share from continuing operations:                   |                        |                                       |        |      |       
|                                                                        | Basic                  | $                                     | (0.53) |      | $      | 0.32
|                                                                        | Diluted                | $                                     | (0.53) |      | $      | 0.32

Diluted earnings per share are computed by increasing the denominator to include additional common stock equivalents. As a result of the loss reported for the three months ended March 31, 2008, 188,427 dilutive common stock equivalents have been excluded from the calculation because their inclusion would be anti-dilutive.

Common stock equivalents representing stock options and restricted stock units (RSUs) of 417,682 shares and 618,929 shares for the three months ended March 31, 2008 and 2007, respectively, were not included in the computation of diluted earnings per share because their prices were greater than the average market price of the Companys common stock during those periods.



6





---

Reclassifications

The Company has made certain reclassifications in the consolidated balance sheet as of December 31, 2007, primarily related to income taxes, to conform to the 2008 presentation.

The following table sets forth the changes made to the accompanying consolidated statement of cash flows for the three months ended March 31, 2007, for a sale-leaseback transaction based on the guidance in SFAS No. 95, Statement of Cash Flows.



|                       |                      |        |                      |   |        |  
|---------------------- | -------------------- | ------ | -------------------- | - | ------ | -
|                       | Investing Activities |        | Financing Activities |  
|                       | (in thousands)       |       
|As previously reported | $                    | (5,400 | )                    | $ | 5,400  |  
|Non-cash adjustment    |                      | 5,400  |                      |   | (5,400 | )
|As adjusted            | $                    |       |                      | $ |       |  

In 2006, the Company decided to close its operations in Florida that were being conducted by its Miami and Ft. Myers subsidiaries and reported in the early stage business segment. The Company made this decision primarily due to a number of operational issues that had resulted in a material negative impact on earnings and in response to actions by local authorities that included an order to demolish the Companys clinical and administrative office building in Miami. The Company vacated and demolished the Miami facility, terminated employees located at these subsidiaries and completed other administrative tasks. The final contract and study was completed in January 2008.

While the Companys wind down and closure of its operations in Miami and Ft. Myers are substantially complete, the remnants of the assets and liabilities from those operations are accounts receivable, land owned in Miami, accounts payable and accrued liabilities. Through December 31, 2007, these operations had been accounted for as discontinued operations. As of March 31, 2008, the assets, liabilities and residual impact to the statement of operations were immaterial. Accordingly, at March 31, 2008, those remaining assets and liabilities have been included with the assets and liabilities of continuing operations. Any changes in those specific assets and liabilities in future reporting periods will be evaluated for materiality and separate financial statement disclosure.

The results of operations of the Miami and Ft. Myers subsidiaries for the three months ended March 31, 2007, are included in the accompanying consolidated statements of operations as Earnings from discontinued operations, net of tax. The following table sets forth the components of these earnings for the three months ended March 31, 2007.



|                                                  |   |                |  
|------------------------------------------------- | - | -------------- | -
|                                                  |   | (in thousands) |  
|Net revenue:                                      |   |                |  
|Direct revenue                                    | $ | 32             |  
|Reimbursed out-of-pocket expenses                 |   |               |  
|Total net revenue                                 |   | 32             |  
|Costs and expenses:                               |   |                |  
|Direct costs                                      |   | (2             | )
|Reimbursable out-of-pocket expenses               |   |               |  
|Selling, general and administrative expenses      |   | 336            |  
|Total costs and expenses                          |   | 334            |  
|Other income (expense), net                       |   | 942            |  
|Earnings before income taxes                      |   | 640            |  
|Income tax expense (benefit)                      |   |               |  
|Earnings from discontinued operations, net of tax | $ | 640            |  
|                                                  |   |                |  





7





---

NOTE B  CREDIT FACILITY

The Company has a Credit Facility, currently in the amount of $45.0 million, with a syndicate of banks that originated in 2004. The Credit Facility has a maturity date of December 22, 2009. The Credit Facility was amended and restated in its entirety in 2005 and has been subsequently amended six times. The latest amendment on March 11, 2008, modified certain provisions to enable the Company to make certain investments and acquisitions.

As of March 31, 2008, the principal balance outstanding on the Credit Facility was zero. Based on the Companys financial performance during the first quarter of 2008, the Company did not meet certain financial requirements of the Credit Facility, and as a result, has entered into a period of default. Due to this default, the Company is not eligible to borrow against the revolving line of credit. Management is currently in discussion with the syndicate to address the default situation. The Company believes that the inability to draw on the Credit Facility will not have a material impact on liquidity or its operations in the near term.

The obligations under the Credit Facility are guaranteed by each of the Companys U.S. subsidiaries and are secured by a lien on the vacant land in Miami, Florida, a pledge of all of the assets of the Companys U.S. operations and U.S. subsidiaries and a pledge of 65% of the stock of certain of the Companys foreign subsidiaries. The U.S. assets collateralizing the Credit Facility amounted to approximately $400.0 million, including goodwill and intangible assets and are included in the consolidated balance sheet as of March 31, 2008.

NOTE C  COMMITMENTS AND CONTINGENCIES

Leases

The Company leases scientific equipment and automobiles under capital lease arrangements from various lessors for periods varying in length from 36 to 60 months. The Company also leases facilities and certain equipment under non-cancelable operating leases, which expire over the next 20 years.

Litigation and Inquiries

On March 12, 2007, the Company received notice that the SEC staff had secured a formal order of private investigation. The formal order relates to revenue recognition, earnings, company operations and related party transactions. The Company has been cooperating fully with the SEC. In late December 2005, the Company received an informal request from the SEC for documents relating to the duties, qualifications, compensation and reimbursement of former officers and employees. This request also asked for a copy of the report to Senator Grassley by the Companys independent counsel. In a second request, sent March 28, 2006, the SEC asked for information regarding related parties and transactions, duties and compensation of various employees, internal controls, revenue recognition and other accounting policies and procedures and selected regulatory filings. As part of its investigation, the SEC staff interviewed several former employees on the topics identified in the formal order. On June 11, 2007, the Company received a subpoena from the SEC for additional accounting documents. The Company has voluntarily complied with these requests and has provided and expects to continue to provide documents to the SEC as requested.

Beginning in late December 2005, a number of class action lawsuits were filed in the United States District Court for the Southern District of Florida and the United States District Court for the District of New Jersey alleging that PDGI and certain of its current and former officers and directors violated federal securities laws (the Federal Securities Actions). The Company was served notice of these lawsuits in early January 2006. On June 21, 2006, the Judicial Panel for Multidistrict Litigation transferred all of the Federal Securities Actions for pre-trial proceedings to the District of New Jersey, where they were later consolidated.

On November 1, 2006, the Arkansas Teachers Retirement System, the lead plaintiff in the Federal Securities Actions, filed a consolidated amended class action complaint (the Amended Complaint). The Amended Complaint alleges that the Company and several of its current and former officers and directors violated Sections 11, 12 (a)(2) and 15 of the Securities Act of 1933, as well as Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The Amended Complaint claims violations of these federal securities laws through misstatements or omissions regarding: the maximum occupancy at the Companys Miami facility; the Miami facilitys purportedly dangerous and unsafe structure; the Companys clinical practices; purported conflicts of interests involving Independent Review Boards used by the Company; related-party transactions and some former executives qualifications.



8





---

On August 1, 2007, the Company issued a press release announcing that it had entered into an agreement to settle the Federal Securities Actions on the principal terms set forth in an Agreement to Settle Class Action (the Settlement Agreement). Pursuant to the terms of the Settlement Agreement, the class will receive approximately $28.5 million (less legal fees, administration and other costs). The Company accrued an estimated liability of $10.4 million during the year ended December 31, 2007, which was not covered by the Companys insurance, associated with the Settlement Agreement and other related litigation. The Company had the option to elect to pay up to $4.0 million of this amount in common stock, or all in cash. The common stock was to be valued according to the volume weighted average closing price for the 10 trading days leading up to the date the district court enters an order formally approving the Settlement Agreement. On December 3, 2007, the Court preliminarily approved the Settlement Agreement. On December 11, 2007, the Company made cash payments to the plaintiffs escrow account in the amount of $0.3 million and on January 11, 2008, the Company made cash payments to the plaintiffs escrow account in the amount of $3.7 million. On March 10, 2008, the Court formally approved the Settlement Agreement and entered Final Judgment. On March 24, 2008, the Company issued 135,870 shares of common stock to the plaintiffs settlement fund to settle the action, or $4.0 million in common stock, the value of such common stock equal to $29.44 per share which was calculated as set forth above. The common stock and cash have not been disbursed to the class. On April 9, 2008, a Notice of Appeal of the Final Judgment was filed. It is uncertain how long the appeals process will take.

Beginning in late December 2005, a total of five stockholder derivative complaints were filed in the United States District Court for the Southern District of Florida and the United States Court for the District of New Jersey against certain of the Companys current and former officers and directors, as well as PDGI (as a nominal defendant) for alleged violations of state and federal law, including breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets, unjust enrichment, disgorgement under the Sarbanes-Oxley Act of 2002 and violation of Section 14(a) of the Securities Exchange Act of 1934 (the Federal Derivative Actions). The Company was served notice of these lawsuits in early January 2006. The Federal Derivative Actions allege that the individual defendants misrepresented and engaged in a conspiracy to misrepresent the Companys business condition, prospects and financial results, failed to disclose its allegedly improper and reckless business practices, such as mismanagement of clinical trials and mistreatment of research participants, used its artificially inflated stock to acquire other companies and complete public offerings and engaged in illegal insider trading.

Beginning in late January 2006, two substantially similar derivative actions were filed in the Florida Circuit Court (the Florida Circuit Court Derivative Action). On June 21, 2006, the Judicial Panel for Multidistrict Litigation transferred the Federal Derivative Actions pursuant to 28 U.S.C. § 1407 for pre-trial proceedings in the District of New Jersey, where they were later consolidated. Such consolidated action is referred to herein as the Federal Derivative Action.

Following the decision of the Judicial Panel for Multidistrict Litigation and the decision to consolidate all of the Federal Derivative Actions in the District of New Jersey, the Florida Circuit Court entered an order staying those cases pending final resolution of the Federal Derivative Action.

A consolidated amended complaint was filed in the Federal Derivative Action on November 13, 2006. On January 11, 2007, the defendants filed a motion to dismiss that amended complaint. On July 24, 2007, the district court denied the defendants motion to dismiss the Federal Derivative Action. On September 17, 2007, the parties sent the Court a letter informing the Court that the parties have engaged in settlement discussions. The parties have agreed to extend the deadline for all defendants to respond to the operative complaint pending settlement negotiations. As a result of the settlement discussions, the Company reached a preliminary agreement to settle the Federal Derivative Action. Under the terms of the agreement, the plaintiffs will receive $2.0 million in cash, of which $1.0 million will be covered by the Companys insurance policy. Under the terms of the agreement, the Company does not admit to any liability by us or any of the Companys current and former directors, officers and employees who were named in the lawsuit.  The agreement has been finalized, but it is not yet signed, and the settlement is subject to court approval and other customary conditions.

If the agreement is not ultimately finalized, the individuals named as defendants in the Federal Derivative Action and the Florida Circuit Court Derivative Action intend to vigorously defend against the lawsuits. As the outcome of these matters is difficult to predict, significant changes in the Companys estimated exposures could occur.



9





---

The Companys attempts to resolve these legal proceedings involve a significant amount of attention from its management, additional cost and uncertainty, and these legal proceedings may result in material damage or penalty awards or settlements, and may have a material and adverse effect on its results of operations, including a reduction in net earnings and a deviation from forecasted net earnings.

Reduction in Workforce

As a result of a short-term decrease in business activity, primarily driven by backlog cancellations, combined with expansions in hiring, the fourth quarter 2007 saw a decline in several metrics used to measure productivity and efficiency, such as billable utilization rates. As a result of these declines and current forecasted business levels, the Company made a strategic decision to reduce staff in both the early and late stage segments, as well as close some office locations and combine others. Job placement assistance is being offered at no charge to employees who are terminated in this action. The staff reductions started in the first quarter 2008 and will be completed in the second quarter 2008. The office closures are expected to be completed by the second quarter 2008.

In March 2008, the Company announced workforce reductions in both the early stage and late stage segments. We recorded a severance charge of $2.0 million in the first quarter 2008, of which $0.4 million impacted the early stage segment and $1.6 million impacted the late stage segment. Early stage costs were recorded in the amounts of $0.1 million in direct costs and $0.3 million in selling, general, and administrative (SG&A) expenses and all late stage costs were recorded in SG&A expenses in the statement of operations for the three months ended March 31, 2008.

The following table sets forth the roll forward of the liability for the three months ended March 31, 2008, in connection with one time termination benefits to employees. This liability is recorded in accrued liabilities in the consolidated balance sheet.



|                                         |  |                |       |             |   |       |   |   |       |  
|---------------------------------------- |  | -------------- | ----- | ----------- | - | ----- | - | - | ----- | -
|                                         |  | Late Stage     |       | Early Stage |   | Total |  
|                                         |  | (in thousands) |      
|Balance at December 31, 2007             |  | $              |      |             | $ |      |   | $ |      |  
|                                         |  |                |       |             |   |       |   |   |       |  
|Charge for one-time termination benefits |  |                | 1,597 |             |   | 358   |   |   | 1,955 |  
|                                         |  |                |       |             |   |       |   |   |       |  
|Less: Benefits paid                      |  |                | (19   | )           |   | (183  | ) |   | (202  | )
|                                         |  |                |       |             |   |       |   |   |       |  
|Balance at March 31, 2008                |  | $              | 1,578 |             | $ | 175   |   | $ | 1,753 |  



In the second quarter of 2008, the Company will incur an additional estimated charge of $1.5 million in connection with office closings in Washington, D.C, and Australia, related to the late stage segment. Under SFAS 146, Accounting for Costs Associated with Exit or Disposal Activities, the liability for the office closures has not been established as of March 31, 2008, because notification criteria were not met at that time. It is intended that the regulatory consulting staff in Washington will continue as full-time employees and the core of the clinical research personnel in Australia will continue as home-based employees. The total costs of these actions are estimated at $0.4 million for the early stage segment and $3.5 million for the late stage segment.



NOTE D  EQUITY

Employee Stock Purchase Plan

The Company has an Employee Stock Purchase Plan (ESPP), which permits eligible employees, excluding executive officers, to purchase up to 550,000 shares of the Companys common stock. Share-based compensation expense recognized under the ESPP was $0.1 million and $0.2 million for the three months ended March 31, 2008 and 2007, respectively. As of March 31, 2008, 143,548 shares of common stock were reserved for future issuance.

As a result of an error in recordkeeping, the amount of shares authorized under the ESPP exceeded the amount of registered shares by 400,000 shares. Unregistered shares are subject to rescission rights for one year after issuance. During the year ended December 31, 2007, the Company issued 134,271 unregistered shares to ESPP participants in two transactions, and such shares were subject to rescission as of December 31, 2007. For the offering period ended December 31, 2006, the Company issued 78,005 shares on January 1, 2007, at $12.89 per share, and for the offering



10





---

period ended June 30, 2007, the Company issued 56,266 shares on July 1, 2007, at $18.75 per share. Accordingly, as of December 31, 2007, the Company classified the amount of $2.1 million as temporary equity in the consolidated balance sheet. During the three months ended March 31, 2008, the Company reclassified $1.0 million of this amount to shareholders equity as the shares issued on January 1, 2007, no longer had rescission rights. Additionally, for the offering period ended December 31, 2007, the Company issued 41,121 shares on January 1, 2008, at $27.10 per share. This sale totaling $1.1 million was recorded in temporary equity as of March 31, 2008.

While the Company believes the possibility of rescission of a portion of the ESPP shares may occur, the repurchase of the shares issued on July 1, 2007, and January 1, 2008, is not solely within the control of the Company. During the third quarter of 2008, the Company will reclassify $1.1 million, adjusted for any repurchases which may occur, from temporary equity to shareholders equity as the shares issued on July 1, 2007, will no longer have rescission rights. During the first quarter of 2009, the remaining value of ESPP shares subject to rescission, adjusted for any repurchases which may occur, will be reclassified from temporary equity to shareholders equity as those shares will no longer be subject to rescission. On April 7, 2008, the Company filed a Form S-8 registration statement with the SEC to register the 400,000 shares of common stock that had been authorized and approved but not registered.

Share-Based Compensation

Share-based compensation expense is recognized on a straight-line basis over the vesting period of the related awards. During the three months ended March 31, 2008 and 2007, the Company recognized compensation expense of $1.3 million and $1.0 million, respectively, for stock options and RSUs. As of March 31, 2008, there was $11.0 million of unrecognized compensation cost related to unvested restricted stock and RSUs, which is being recognized over a weighted-average period of 2.2 years. As of March 31, 2008, there was $2.5 million of unrecognized compensation cost related to stock options outstanding, which is being recognized over a weighted-average period of 2.6 years.

On March 4, 2008, the Company granted awards to executive officers and certain management in the form of stock options and RSUs. Stock options granted under the 1999 Stock Option Plan (the 1999 Plan) vest ratably over three years and expire between seven and ten years or three months after separation of service. RSUs vest ratably over five years. In certain situations any unvested RSUs or options vest immediately upon the occurrence of a change in employment status. As of March 31, 2008, there were 180,725 shares of common stock available for issuance under the 1999 Plan.

The fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton pricing model. The following table sets forth the weighted-average assumptions for options granted during the three months ended March 31, 2008. There were no stock options granted during the three months ended March 31, 2007.



|                        |          
|----------------------- | ---------
|Risk-free rate (1)      | 2.36%    
|Expected term (2)       | 4.5 years
|Expected volatility (3) | 59.7%    



(1)

The risk-free rate is based upon the rate on a zero coupon U.S. Treasury bill, for periods within the contractual life of the option, in effect at the time of grant.

(2)

The Company has significantly changed the terms of the stock options granted to employees over the years such that historical exercise data is not available. As a result, the expected term of the option is determined using the simplified method provided by SEC Staff Accounting Bulletin No. 107, the vesting terms and a contractual life of the respective option.

(3)

Expected volatility is based on the daily historical volatility of the Companys stock price, over a period equal to the expected life of the option.



11





---

The following table sets forth stock option activity and related information during the three months ended March 31, 2008.



|                                       |  |                                  |   |                                  |       |                                              |     
|-------------------------------------- |  | -------------------------------- | - | -------------------------------- | ----- | -------------------------------------------- | ----
|                                       |  | Number of
Options
(in thousands) |   | Weighted-
Average
Exercise
Price |       | Weighted-
Average
Remaining
Contractual
Life
|Outstanding at beginning of the period |  | 914                              |   | $                                | 27.29 |                                              | 3.27
|Granted                                |  | 101                              |   | $                                | 29.47 |                                              |     
|Exercised                              |  | (128                             | ) | $                                | 11.87 |                                              |     
|Forfeited and expired                  |  | (60                              | ) | $                                | 17.80 |                                              |     
|Outstanding at end of the period       |  | 827                              |   | $                                | 30.62 |                                              | 3.40
|Exercisable at end of the period       |  | 637                              |   | $                                | 31.33 |                                              | 2.42

The following table sets forth a summary of non-vested restricted stock and RSU activity and related information during the three months ended March 31, 2008.



|                                      |                                                |                |                                         |   |      
|------------------------------------- | ---------------------------------------------- | -------------- | --------------------------------------- | - | -----
|                                      | Restricted 
Stock and 
Restricted 
Stock Units |                | Weighted-
Average
Grant-Date
Fair Value
|                                      |                                                | (in thousands) |                                         |   |      
|Non-vested at beginning of the period |                                                | 282            |                                         | $ | 23.62
|Granted                               |                                                | 190            |                                         | $ | 29.47
|Vested                                |                                                |               |                                         | $ |     
|Forfeited                             |                                                |               |                                         | $ |     
|Non-vested at end of the period       |                                                | 472            |                                         | $ | 25.97

NOTE E  INCOME TAXES

The Companys effective tax rate for the three months ended March 31, 2008 was an expense of 11.4% compared to 22.6% in the corresponding 2007 period. For the three months ended March 31, 2008, the loss from continuing operations before income taxes consisted of a domestic loss of $8.9 million and foreign earnings of $0.3 million. The Company continues to maintain a full valuation allowance against the domestic net deferred tax assets. For the three months ended March 31, 2008, the Company did not record any tax benefits associated with the domestic operating loss and recorded consolidated tax expense of $1.0 million, which was primarily attributable to state taxes, taxes on foreign earnings and tax expense related to uncertain tax positions. The overall reduction in income tax expense for the first quarter 2008 as compared to the first quarter 2007 was due to reduced foreign earnings as compared to the same period in the prior year.

The Company also continues to maintain a partial valuation allowance relating to research and development tax credits resulting from its Canadian operations and net operating losses on certain foreign subsidiaries. The Company established the valuation allowance against these carryforwards based on an assessment that it is more likely than not that these benefits will not be realized.

The historical practice of the Company has been to leave unremitted foreign earnings invested indefinitely outside the U.S. Hence, the Company has elected under APB Opinion No. 23, Accounting for Income Taxes  Special Areas, to deem earnings and profits related to foreign subsidiaries as permanently reinvested. Accordingly, the Company has made no provision for U.S. income taxes that might result from repatriation of these earnings. As of March 31, 2008, the undistributed earnings of foreign subsidiaries were $82.1 million.

Under FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48), the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

The Companys U.S. subsidiaries have joined in the filing of a U.S. federal consolidated income tax return since acquisition. The U.S. federal statute of limitations remains open for the years 2002 onward. The Company is subject to ongoing tax audits by the Internal Revenue Service for tax years ending December 31, 2004 and 2005. The



12





---

Company is under a provincial tax audit in Canada for tax years 2003  2005. It is expected that the amount of unrecognized tax benefits will change in the next 12 months; however the Company cannot be certain that the changes in FIN 48 will not impact the effective tax rate.

NOTE F  SEGMENT REPORTING

The Company has two reportable business segments, early stage and late stage. The early stage segment consists of Phase I clinical trial services and bioanalytical laboratory services, including early clinical pharmacology. The late stage segment consists of Phase II through Phase IV clinical trial services, including a comprehensive array of services including data management and biostatistics, medical and scientific affairs, regulatory affairs and clinical information technology and consulting services. The Company evaluates its segment performance based on direct revenue, operating margins and net earnings before income taxes. Accordingly, the Company does not include the impact of depreciation and amortization expense, interest income (expense), foreign currency exchange transaction gain (loss), other income (expense) and income taxes in segment profitability.

The following table sets forth operations by segment for the three months ended March 31, 2008 and 2007.



|                                                                |  |                |         |            |   |                        |   |       |        |   |   |         |  
|--------------------------------------------------------------- |  | -------------- | ------- | ---------- | - | ---------------------- | - | ----- | ------ | - | - | ------- | -
|                                                                |  | Early Stage    |         | Late Stage |   | Corporate 
Allocations |   | Total |       
|Direct revenue                                                  |  | (in thousands) |        
|2008                                                            |  | $              | 37,632  |            | $ | 49,168                 |   | $     |       |   | $ | 86,800  |  
|2007                                                            |  | $              | 29,704  |            | $ | 55,077                 |   | $     |       |   | $ | 84,781  |  
|Earnings (loss) from continuing operations                      |  |                |         |            |   |                        |   |       |        |   |   |         |  
|2008                                                            |  | $              | 2,611   |            | $ | (3,485                 | ) | $     | (6,610 | ) | $ | (7,484  | )
|2007                                                            |  | $              | 5,041   |            | $ | 8,790                  |   | $     | (5,218 | ) | $ | 8,613   |  
|Earnings (loss) from continuing operations 
before income taxes |  |                |         |            |   |                        |   |       |        |   |   |         |  
|2008                                                            |  | $              | 2,674   |            | $ | (3,919                 | ) | $     | (7,437 | ) | $ | (8,682  | )
|2007                                                            |  | $              | 5,349   |            | $ | 9,314                  |   | $     | (6,759 | ) | $ | 7,904   |  
|Total assets                                                    |  |                |         |            |   |                        |   |       |        |   |   |         |  
|2008                                                            |  | $              | 152,617 |            | $ | 435,230                |   | $     | 8,353  |   | $ | 596,200 |  
|2007                                                            |  | $              | 146,394 |            | $ | 418,036                |   | $     | 6,222  |   | $ | 570,652 |  







13





---



Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read together with the consolidated financial statements and related notes included in this report on Form 10-Q for the quarter ended March 31, 2008, and in our Annual Report on Form 10-K for the year ended December 31, 2007. This discussion contains forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those anticipated in the forward-looking statements as a result of certain factors, including, but not limited to, those in the discussion on forward-looking statements below.

Overview

We operate our business in two segments, early stage and late stage. Our early stage segment consists primarily of our Phase I clinical trial services and our bioanalytical laboratory services, including early clinical pharmacology. Our late stage segment consists primarily of Phase II through Phase IV clinical trial services and a comprehensive array of related services, including data management and biostatistics, medical and scientific affairs, regulatory affairs and clinical information technology and consulting services. For additional information about segments, see Note F to the consolidated financial statements.

During 2006, we discontinued operations at our Miami and Ft. Myers facilities. All financial results for the three months ended March 31, 2008, include any residual activity from discontinued operations, such as collections of outstanding accounts receivable and property tax payments on the vacant land in Miami. In the first quarter of 2008, there was no activity related to any discontinued operation that was considered material. In addition, we have made certain balance sheet reclassifications, primarily related to income taxes, to the 2007 financial information to conform to the 2008 presentation.

Our net revenue consists primarily of fees earned for services performed under contracts with branded pharmaceutical, biotechnology, medical device and generic drug company clients. A portion of our contract fee is generally due upon signing of the contract, and the majority of the contract fee is then paid in installments upon the achievement of certain agreed upon performance milestones. Relative to our early stage contracts, our late stage contracts are generally larger and longer in duration, and our late stage segment typically receives larger advance payments. Our contracts are generally terminable immediately or after a specified period following notice by the client. These contracts usually require payment to us of expenses to wind down a study and fees earned to date. Most of the contracts in our early stage segment are of short duration; however, our late stage segment typically performs services under long-term contracts, which are subject to a greater risk of delay or cancellation.

In our late stage business, we report revenue line items consisting of direct revenue and reimbursed out-of-pocket expenses, together with an expense line item for reimbursable out-of-pocket expenses, which consist of travel and other expenses related to studies that are reimbursed by our clients.

We record our recurring operating expenses in three primary categories: (i) direct costs, (ii) selling, general and administrative expenses and (iii) reimbursable out-of-pocket expenses. Direct costs consist primarily of participant fees and associated expenses, direct labor and employee benefits, facility costs, depreciation associated with facilities and equipment used in conducting trials and other costs and materials directly related to contracts. Direct costs as a percentage of net revenue vary from period to period due primarily to the varying mix of contracts and services performed and to the percentage of revenues arising from our early stage operations, which generally have higher direct costs. Selling, general and administrative expenses consist primarily of administrative payroll, except for the late stage segment, overhead, advertising, legal and accounting expenses, travel, depreciation and amortization of intangibles. The late stage segment includes all payroll-related costs as part of direct costs, and all office costs and depreciation as part of selling, general and administrative expenses.

The gross profit margins on our contracts vary depending upon the nature of the services we perform for our clients. Gross profit margins for our early stage segment generally tend to be higher than those for our late stage segment and other services we perform. Within our early stage segment, our gross profit margins are generally higher for trials that involve a larger number of participants, a longer period of study time or the performance of more tests. Gross profit margins for our services to branded drug clients generally tend to be higher than those for generic drug clients. In addition, our gross profit margins vary based upon our mix of domestic and international business. Gross profit margins are calculated by dividing gross profit (direct revenue less direct costs) by direct revenue.



14





---

Critical Accounting Estimates

We make estimates and assumptions in the preparation of our consolidated financial statements, which affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and revenues and expenses for the applicable period ended date. Future events and their effects cannot be determined with certainty; therefore, the determination of estimates requires the exercise of judgment. Actual results could differ from those estimates and such differences may be material to our consolidated financial statements. Management continually evaluates its estimates and assumptions, which are based on historical experience and other factors we believe to be reasonable under the circumstances. These estimates and our actual results are subject to the Risk Factors contained in Item 1A of this report. There have been no material changes in our critical accounting estimates or our application of these estimates during the three months ended March 31, 2008.



Results of Operations



Three Months Ended March 31, 2008 Compared to Three Months Ended March 31, 2007



The following table sets forth our results of operations both numerically and as a percentage of direct revenue for the three months ended March 31, 2008 and 2007.



|                                                                                     |  |                                       |         |      |       |    |  |        |   |       |  
|------------------------------------------------------------------------------------ |  | ------------------------------------- | ------- | ---- | ----- | -- |  | ------ | - | ----- | -
|                                                                                     |  | 2008                                  |         | 2007 |      
|                                                                                     |  | (In thousands, except per share data) |        
|Direct revenue                                                                       |  | $                                     | 86,800  |      | 100.0 | %  |  | 84,781 |   | 100.0 | %
|Direct costs                                                                         |  |                                       | 60,893  |      | 70.2  |    |  | 50,478 |   | 59.5  |  
|Selling, general and administrative expenses                                         |  |                                       | 33,391  |      | 38.5  |    |  | 25,690 |   | 30.3  |  
|Total other expense, net                                                             |  |                                       | (1,198  | )    | (1.4  | )  |  | (709   | ) | (0.8  | )
|(Loss) earnings from continuing operations before income taxes                       |  |                                       | (8,682  | )    | (10.0 | )  |  | 7,904  |   | 9.3   |  
|Income tax expense                                                                   |  |                                       | 995     |      | 1.1   |    |  | 1,783  |   | 2.1   |  
|(Loss) earnings from continuing operations before minority interest in joint venture |  |                                       | (9,677  | )    | (11.1 | )  |  | 6,121  |   | 7.2   |  
|Minority interest in joint venture                                                   |  |                                       | 422     |      | 0.5   |    |  | 129    |   | 0.2   |  
|(Loss) earnings from continuing operations                                           |  |                                       | (10,099 | )    | (11.6 | )  |  | 5,992  |   | 7.1   |  
|Earnings from discontinued operations, net of tax                                    |  |                                       |        |      |       |    |  | 640    |   | 0.8   |  
|Net (loss) earnings                                                                  |  | $                                     | (10,099 | )    | (11.6 | )% |  | 6,632  |   | 7.8   | %
|(Loss) earnings per share from continuing operations:                                |  |                                       |         |      |       |    |  |        |   |       |  
|Basic                                                                                |  | $                                     | (0.53)  |      |       |    |  | 0.32   |   |       |  
|Diluted                                                                              |  | $                                     | (0.53)  |      |       |    |  | 0.32   |   |       |  



Direct Revenue

Direct revenue, which does not include reimbursed out-of-pocket expenses, was $86.8 million for the three months ended March 31, 2008, an increase of 2.4% from $84.8 million for the corresponding 2007 period. The increase is attributable to growth in the early stage segment, partially offset by lower revenues in the late stage segment primarily due to project cancellations.

Direct revenue in the early stage segment was $37.6 million for the three months ended March 31, 2008, compared to $29.7 million for the corresponding 2007 period. This increase of 26.7% is primarily attributable to higher direct revenue in the laboratories and clinics. The performance of our bioanalytical laboratories continues to grow, with increasing sample volumes in the first quarter 2008 compared to the corresponding 2007 period. Direct revenue in the late stage segment was $49.2 million for the three months ended March 31, 2008, compared to $55.1 million in the corresponding 2007 period. This decrease of 10.7% is primarily the result of project cancellations in our backlog totaling $30.0 million in the first quarter 2008 and $29.0 in the fourth quarter 2007. The majority of the cancellations in the first quarter 2008 resulted from biotech companies deciding not to continue studies. This was unlike the fourth quarter 2007 where the majority of the cancellations related to large pharmaceutical companies. The combined cancellations negatively impacted direct revenue by approximately $6.6 million in the first quarter 2008 and are expected to negatively impact 2008 revenues by approximately $29.6 million. The majority of the cancellations in the first quarter 2008 and in the fourth quarter 2007 were primarily due to issues surrounding the efficacy of the drugs and not related to our performance. We expect to be



15





---

impacted by the unusually high level of cancellations, which occurred over the last two quarters, throughout the remainder of the year, but we believe our strengthened backlog indicates a trend of long-term growth.

For the three months ended March 31, 2008, direct revenue was $34.0 million from U.S. operations and $52.8 million from foreign operations compared to $38.7 million from U.S. operations and $46.1 million from foreign operations in the corresponding 2007 period.

Direct Costs

Direct costs increased to $60.9 million for the three months ended March 31, 2008, compared to $50.5 million for the corresponding 2007 period. For the three months ended March 31, 2008, direct costs as a percentage of direct revenue increased to 70.2% from 59.5% in the corresponding 2007 period. This increase is attributable to higher costs in both the early and late stage segments. Increased direct costs in the early stage segment are primarily due to higher expenses related to the expansion of our clinics and laboratories in Canada, including additional investments in clinical personnel. Increased costs in the late stage segment are primarily attributable to higher compensation and related benefit costs.

Gross Profit Margins

Gross profit margins as a percentage of direct revenue was 29.8% for the three months ended March 31, 2008, compared to 40.5% for the corresponding 2007 period. Since we perform a wide variety of services which carry different gross margins, our margins will vary from quarter-to-quarter and year-to-year based upon the mix of these contracts, our capacity levels at the time we begin the projects and the amount of revenue generated for each type of service we perform. Even within category types, the amount of gross margins generated might vary due to the unique nature and size of each contract and project.

During the three months ended March 31, 2008, the early stage segment had higher than expected direct costs, partially offset by increased direct revenue, which resulted in decreased profit margins compared to the corresponding 2007 period. A number of clinical projects were rescheduled, postponed or cancelled during the latter part of the fourth quarter 2007. Our clinics were staffed to run these studies and when the projects were rescheduled, postponed or canceled, the clinics operated at a lower than expected utilization level, which negatively impacted the segment's margins. Of these projects, approximately 50% were started and completed in the first quarter 2008, while the remainder have been either cancelled or postponed to later periods. We believe these shifts in project timing are temporary, and we believe there has not been a systemic change in market conditions that would impact continued growth of direct revenue in the early stage segment, which was up 26.7% in the first quarter 2008 compared to the corresponding 2007 period. Profit margins in the late stage segment decreased as a result of project cancellations and increased compensation and related benefit costs.

In January 2008, we acquired certain assets of Princeton Bioanalytical Laboratory, LLC, including laboratory equipment and procedural documentation. With the development of the laboratory, we will add macromolecule analysis capabilities to our existing small molecule services. In addition, the acquisition also enabled us to initiate method development and production enhancements in our ligand-binding laboratory in Canada.

Selling, General and Administrative Expenses

Selling, general and administrative, or SG&A, expenses increased to $33.4 million for the three months ended March 31, 2008, compared to $25.7 million for the corresponding 2007 period. As a percentage of direct revenue, SG&A expenses increased to 38.5% in the first quarter 2008 from 30.3% in the first quarter 2007.

In March 2008, we announced workforce reductions in both the early stage and late stage segments. We recorded a severance charge of $2.0 million in the first quarter 2008, of which $0.4 million impacted the early stage segment ($0.3 million recorded in SG&A expenses and $0.1 million recorded in direct costs) and $1.6 million impacted the late stage segment. In the second quarter of 2008, we will incur an additional estimated charge of $1.5 million in connection with office closings in Washington, D.C, and Australia. It is intended that our regulatory consulting staff in Washington will continue as full-time employees and the core of the clinical research personnel in Australia will continue as home-based employees. We expect that the favorable impact of implementing these cost reduction strategies will be realized beginning in the third quarter of 2008.



16





---

Corporate SG&A expenses for the three months ended March 31, 2008 were $6.6 million compared to $5.2 million in the corresponding 2007 period. This increase of $1.4 million is attributable to an increase in non-cash compensation costs and higher professional fees, partially offset by a decrease in legal fees related to the SEC investigation.

Interest Income and Interest Expense

Interest expense decreased to $1.4 million for the three months ended March 31, 2008, compared to $1.6 million in the corresponding 2007 period. This decrease is primarily attributable to a reduction of interest expense on our line of credit as there were no borrowings under the line during the first quarter 2008.

Interest income for the three months ended March 31, 2008, was $0.5 million and remained consistent compared to the corresponding 2007 period.

Foreign Currency Exchange Transactions

We do not enter in currency transactions with the intent of speculating or trading. Our consolidated financial statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar affect the translation of each foreign subsidiarys financial results into U.S. dollars for purposes of reporting in the consolidated financial statements. Our foreign subsidiaries translate their financial results from local currency into U.S. dollars in the following manner: (a) income statement accounts are translated at average exchange rates for the period; (b) balance sheet asset and liability accounts are translated at end of period exchange rates; and (c) equity accounts are translated at historical exchange rates. Translation in this manner affects the shareholders equity account referred to as the foreign currency translation adjustment account. This account exists only in the foreign subsidiarys U.S. dollar balance sheet and is necessary to keep in agreement the foreign subsidiaries balance sheets. If foreign exchange rates remained at the 2007 year-end spot exchange rate for translation, early stage revenues for the first quarter 2008 would have been reduced by $0.5 million when translated into U.S. dollars, and late stage revenues for the first quarter 2008 would have been reduced by $0.1 million when translated into U.S. dollars. Similarly, early stage direct costs for the first quarter 2008 would have been reduced by $0.5 million and late stage direct costs for the first quarter 2008 would have been reduced by $0.2 million. Further, early stage SG&A expenses for the first quarter 2008 would have been reduced by $0.2 million. The impact of translation on late stage SG&A expenses for the first quarter 2008 was not material. The net effect on earnings from operations from translation of functional currency to reporting currency for the first quarter 2008 was earnings of $0.1 million in the early stage and $0.2 million in the late stage.

Foreign currency exchange transaction loss was $0.4 million for the three months ended March 31, 2008, compared to a gain of $0.4 million in the corresponding 2007 period. This change was primarily due to the U.S. dollar weakening approximately 1.1% against the Euro and 4.3% against the Swiss Franc during the first quarter 2008. Within our early stage segment operating in Canada, essentially all costs are in Canadian dollars, while a significant portion of direct revenue is either in U.S. dollars or Euros. Similarly, in the late stage segment in Europe, costs are primarily in Euros and Swiss Francs, while a significant portion of direct revenue is in U.S. dollars. During the three months ended March 31, 2008, we entered into foreign currency forward contracts to hedge exposure related to receivables denominated in currencies other than the functional currency. Due to the nature and short-term duration of these contracts, we did not elect to apply hedge accounting under SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, for these transactions.

Income Taxes

Our effective tax rate for the three months ended March 31, 2008 was an expense of 11.4% compared to 22.6% in the corresponding 2007 period. For the three months ended March 31, 2008, the loss from continuing operations before income taxes consisted of a domestic loss of $8.9 million and foreign earnings of $0.3 million. We continue to maintain a full valuation allowance against the domestic net deferred tax assets. For the three months ended March 31, 2008, we did not record any tax benefits associated with the domestic operating loss and recorded consolidated tax expense of $1.0 million, which was primarily attributable to state taxes, taxes on foreign earnings and tax expense related to uncertain tax positions. The overall reduction in income tax expense for the first quarter 2008 as compared to the first quarter 2007 was due to reduced foreign earnings as compared to the same period in the prior year.



17





---

We also continue to maintain a partial valuation allowance relating to research and development tax credits resulting from our Canadian operations and net operating losses on certain foreign subsidiaries. We established the valuation allowance against these carryforwards based on an assessment that it is more likely than not that these benefits will not be realized.

We receive significant tax credits from the government of Canada relating to our research and development expenses. These credits and tax assets reduce our tax liability in Canada. We expect the nature of our early stage business and the generation of significant tax credits will continue; however, we cannot be assured of the future amount of these credits due to the mix of contracts and the related amounts of research and development activity.

We remain subject to potential examination in federal, state and foreign jurisdictions in which we conduct operations and file tax returns. We believe that the results of any current or prospective audits will not have a material adverse effect on our financial position or results of operations as adequate reserves have been provided to cover any potential exposures related to these audits.

We operate in the U.S. and in numerous taxing jurisdictions worldwide, many with lower tax rates than the U.S. We expect (i) the nature of our business in Canada and the generation of Canadian tax credits to continue and (ii) PharmaNet Inc., our late stage subsidiary to continue generating the majority of its profits in taxing jurisdictions with lower effective tax rates. We also have valuation allowances against certain material deferred tax assets. We cannot be certain that changes in our operating income shifts in the location of the performance of work or other factors such as FIN 48 will not impact the effective tax rate.

Earnings (Loss) Per Share

The weighted average number of shares outstanding used in computing earnings per share on a diluted basis was 19.2 million shares for the three months ended March 31, 2008, an increase from 18.9 million shares in the corresponding 2007 period. This increase resulted primarily from stock option exercises and the issuance of stock options and RSUs. In addition, we issued 0.1 million shares in March 2008 in connection with the settlement of the class action litigation.

Liquidity and Capital Resources

As of March 31, 2008, cash and cash equivalents totaled $63.9 million and working capital was $85.9 million, compared to cash, cash equivalents and marketable securities of $80.2 million and working capital, excluding the assets and liabilities from discontinued operations, of $81.9 million as of December 31, 2007. For the three months ended March 31, 2008, net cash used in operating activities was $20.1 million compared to $6.9 million for the corresponding 2007 period. This change is primarily due to decreases in net earnings from continuing operations of $16.1 million and operating liabilities of $20.9 million, partially offset by decreases in operating assets of $22.2 million. During the three months ended March 31, 2008, we made cash payments of $3.7 million and issued common stock valued at $4.0 million to the plaintiffs in the settlement of the class action litigation. Such amounts had been recorded as accrued liabilities in the consolidated balance sheet as of December 31, 2007.

For the three months ended March 31, 2008, net cash provided by investing activities was $0.7 million compared to net cash used in investing activities of $8.0 million for the corresponding 2007 period. This change was primarily due to proceeds of $2.5 million from the sale of marketable securities in the first quarter 2008 compared to purchases of marketable securities of 2.6 million for the corresponding 2007 period. Purchases of property and equipment decreased to $1.7 million for the first quarter 2008 compared to $5.4 million for the corresponding 2007 period.

For the three months ended March 31, 2008, net cash provided by financing activities was $1.8 million compared to $5.3 million for the corresponding 2007 period. The decrease is primarily due to a reduction in borrowings on the line of credit of $5.0 million, offset by proceeds recognized on stock issued under option plans, the ESPP and restricted stock awards which increased $1.0 million compared to the corresponding 2007 period.

We have a $45.0 million Credit Facility with a syndicate of banks that originated in 2004. The Credit Facility has a maturity date of December 22, 2009. The Credit Facility was amended and restated in its entirety in 2005 and has been subsequently amended six times. The latest amendment, on March 11, 2008, modified certain provisions to enable us to make certain investments and acquisitions.



18





---

The Fourth Amendment on October 14, 2006, substantially modified certain financial covenants and conditions in the Credit Facility to reflect our then-current operations and business needs. The material terms of the amendment (i) required us to provide the Bank (as defined) with additional financial reporting, (ii) permitted us to enter into a sale-leaseback transaction for our Quebec City facility, and (iii) would require a temporary reduction in the amount of borrowing capacity under the Credit Facility to $22.5 million in the event our trailing twelve-month EBITDA (as defined) is materially below, by a certain percentage, the forecasts we provide to the Bank. If the total amount of our outstanding loans exceeds $22.5 million at the time of the occurrence of such an event, we have no immediate obligation to repay these loans. If the trailing twelve-month EBITDA exceeds this threshold in future periods, the full borrowing capacity of the Credit Facility would be restored to $45.0 million. In conjunction with this amendment, the Applicable Margin (as defined) with respect to LIBOR loans was increased by 25 basis points to 3.25% and the Applicable Margin with respect to revolving loans that are prime rate loans was increased by 25 basis points to 2.25%, subject to change based upon certain leverage ratios.

As of March 31, 2008, the principal balance outstanding on the Credit Facility was zero. Based on our financial performance during the first quarter 2008, we were unable to meet certain financial requirements of the Credit Facility, and as a result, have entered into a period of default. Due to this default, we are not eligible to borrow against the revolving line of credit. We are currently in discussions with the Banks to address the default situation. Management believes that the inability to draw on the Credit Facility will not have a material impact on our liquidity or operations in the near term.

The obligations under the Credit Facility are guaranteed by each of our U.S. subsidiaries, are secured by a lien on the vacant land in Miami, Florida, a pledge of all of the assets of our U.S. operations and U.S. subsidiaries and a pledge of 65% of the stock of certain of our foreign subsidiaries. The U.S. assets collateralizing the Credit Facility amounted to approximately $400.0 million, including goodwill and intangible assets and are included in the consolidated balance sheet as of March 31, 2008.

We have issued and outstanding $143.8 million principal amount of 2.25% Convertible Senior Notes due 2024, or the Notes. The Notes are unsecured senior obligations and are effectively structurally subordinated to all existing and future secured indebtedness, and to all existing and future liabilities of subsidiaries, including trade payables. We capitalized all costs related to the issuance of the Notes in 2004 and have been amortizing these costs on a straight-line basis over the expected term, which approximates the effective interest method. Interest is payable in arrears semi-annually on February 15 and August 15 of each year.

The Notes are convertible at any time prior to maturity into cash and, if applicable, shares of common stock based upon an initial conversion rate of 24.3424 shares per $1,000 in principal amount, or an initial conversion price of $41.08 per share. Subject to adjustment in certain circumstances, the maximum number of shares that can be issued upon conversion is 3.1 million. Upon conversion, holders of the Notes will be entitled to receive cash up to the principal amount and, if applicable, shares of common stock pursuant to a formula contained in the indenture. On each of August 15, 2009, 2014 and 2019, holders may require us to repurchase all or a portion of their Notes at a purchase price in cash equal to 100% of the principal amount, plus accrued and unpaid interest. On or after August 15, 2009, we may, at our option, redeem the Notes in whole or in part for cash at a redemption price equal to 100% of the principal amount, plus accrued and unpaid interest. If a majority of the holders require us to repurchase their outstanding Notes, we may have to seek additional financing, depending on the amount of the Notes to be repurchased and the amount of cash or other liquid assets available at that time. We are currently evaluating alternative financing arrangements.

Based upon our cash balances and cash flows from operations, we believe we have adequate working capital to meet our operational needs for the next 12 months.

In order to provide a liquidity metric that enables investors to benchmark us against others in the industry, we calculate days sales outstanding, or DSO, for each period. DSO is calculated by taking the consolidated accounts receivable balance at the end of a period and subtracting both short-term and long-term client advances at the end of the period. The resulting number is divided by average net revenue per calendar day for the period. As of March 31, 2008, our DSO was 41 days compared to 36 days as of December 31, 2007. Accounts receivable, net of client advances, decreased $3.0 million, while daily revenue decreased $0.2 million, which resulted in a higher DSO.

Capital Expenditures and Commitments

During the three months ended March 31, 2008, capital expenditures, excluding non-cash additions of $1.1 million, were $1.7 million compared to $5.4 million for the corresponding 2007 period. We expect to purchase



19





---

between $11.2 million and $13.2 million in capital assets during the remainder of 2008, consisting primarily of new bioanalytical laboratory and computer equipment.

Off-Balance Sheet Commitments

In the normal course of business, we enter into contractual commitments to purchase materials and services from suppliers in exchange for favorable pricing arrangements or more beneficial terms. As of March 31, 2008, these non-cancelable purchase obligations were not materially different from those disclosed in the Contractual Obligations table contained in our Annual Report on Form 10-K for the year ended December 31, 2007.

Under our agreement with our joint venture partner in Spain, we are required to fund the working capital of Anapharm Europe, S.L. Since that operation generates sufficient cash flow from operations, we have not had to provide it any working capital during the three months ended March 31, 2008 nor do we expect to be required to do so in the immediate future.

Recent Accounting Pronouncements

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157), which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  In addition, the statement establishes a framework for measuring fair value and expands disclosure about fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those years, except that FASB Staff Position 157-2 delayed the effective date of SFAS 157 until fiscal years beginning after November 18, 2008, for non-financial assets and liabilities except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. Accordingly, effective January 1, 2008, we adopted this limited provision of SFAS 157. We are currently evaluating the impact of SFAS 157 for non-financial assets and liabilities. Refer to Note A to the consolidated financial statements for a further discussion regarding the adoption of SFAS 157.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (SFAS 159). SFAS 159 provides companies with an option to report selected financial assets and liabilities at fair value. Furthermore, SFAS 159 establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. We adopted SFAS 159 in the interim period beginning January 1, 2008. The adoption did not have a material effect on our consolidated financial position, results of operations or cash flows during the three months ended March 31, 2008.

Forward-Looking Statements

Certain statements made in this report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, words such as seek, intend, believe, plan, estimate, expect, anticipate and other similar expressions are forward-looking statements within the meaning of this act. Some or all of the results anticipated by these forward-looking statements maynot occur. Factors that could cause or contribute to such differences include, but are not limited to:

·

industry trends and information;

·

our ability to implement our business strategy;

·

our ability to leverage our strong reputation;

·

developments with respect to the SECs inquiry and derivative lawsuits;

·

our ability to successfully achieve and manage the technical requirements of specialized clinical trial services;

·

regulatory changes;

·

changes affecting the clinical research industry;

·

an increase or reduction in outsourcing by pharmaceutical and biotechnology companies;

·

our ability to compete internationally in attracting clients in order to develop additional business;

·

our evaluation of our backlog and the potential cancellation of contracts;

·

our ability to retain and recruit new employees;

·

our clients ability to provide the drugs and medical devices used in our clinical trials;

·

our assessment of our effective tax rate and tax valuation allowances;

·

our future effective tax rate;

·

our anticipated 2008 capital expenditures;



20





---

·

the need for us to repurchase any unregistered securities which we sold in violation of securities laws,

·

our ability to remediate our material weakness;

·

our financial guidance;

·

the impact of foreign currency transaction costs and the effectiveness of any hedging strategies that we implement; and

·

the national and international economic climate as it affects drug development operations.

The results anticipated by any or all of these forward-looking statements might not occur. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise, except as required by applicable laws and regulation. For more information regarding some of the ongoing risks and uncertainties of our business, see Item 1A Risk Factors of this report and our other filings with the SEC.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

We are exposed to risks associated with market rates and prices, interest rates and credit in the ordinary course of business. We are also exposed to currency risk due to our foreign operations. Our financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, convertible senior notes and notes payable. As of March 31, 2008, the fair value of these instruments approximated their carrying amounts, except for the convertible senior notes which were at 95% of par value based on the market trading price on that date. We have not entered into any market risk sensitive instruments for trading purposes.

Market Risk

We have invested in marketable securities which we classify as available-for-sale and carry at fair value based on quoted market prices. We are exposed to adverse changes in the market value of such securities while held by us; however, during the three months ended March 31, 2008 and 2007, unrealized holding losses were insignificant. As of March 31, 2008, we did not have any investments in marketable securities; however as of December 31, 2007, we had such investments in the amount of $2.7 million.

Financial instruments that potentially subject us to credit risk consist primarily of trade receivable, cash equivalents and short-term investments. We perform services and extend credit based on an evaluation of the clients financial condition without requiring collateral. Exposure to losses on receivables varies by client based on the financial condition of each client. We monitor exposure to credit losses and maintain allowances for anticipated losses considered necessary under the circumstances. From time to time, we maintain cash balances with financial institutions in amounts that exceed federally insured limits. To mitigate these risks, we maintain cash and cash equivalents with various financial institutions.

Currency Risk

We operate on a global basis which exposes us to various types of currency risks. From time to time, contracts may be denominated in a currency different from the local currency. Two specific transaction risks arise from the nature of the contracts we have with our customers. The first risk occurs as revenue recognized for services rendered is denominated in a currency different from the currency in which our expenses are incurred. As a result, our net service revenues and resulting net earnings or loss can be affected by fluctuations in exchange rates.

The second risk results from the passage of time between the invoicing of customers under these contracts and the ultimate collection of payments against such invoices. Because the contract may be denominated in a currency other than the local currency, we recognize a receivable at the time of invoicing in the local currency equivalent of the foreign currency invoice amount. Changes in exchange rates from the time the invoice is prepared until the payment is received from the customer will result in our receiving either more or less in local currency than the local currency equivalent of the invoice amount. This difference is recognized as a foreign currency transaction gain or loss, as applicable, and is reported in Other income (expense) in the consolidated statements of operations.

Our consolidated financial statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar affect the translation of each foreign subsidiarys financial results into U.S. dollars for purposes of reporting in the consolidated financial statements. Our foreign subsidiaries translate their financial results from the local currency into U.S. dollars in the following manner: (a) income statement accounts are translated at average exchange rates for the period; (b) balance sheet asset and liability accounts are translated at end of period exchange rates; and (c) equity accounts are translated at historical exchange rates. Translation in this manner affects the shareholders equity account referred to as the foreign



21





---

currency translation adjustment account. This account exists only in the foreign subsidiaries U.S. dollar balance sheets and is necessary to keep the foreign subsidiaries balance sheets in agreement.

We have adopted a foreign currency risk hedging policy and we have entered into foreign currency forward contracts to mitigate this risk. We have implemented systems and processes to further mitigate this risk; however we continue to be affected by foreign currency exchange volatility.

Interest rate risk

We have a $45.0 million Credit Facility with a syndicate of banks. The interest rate on the facility is variable and is based on LIBOR and the prime rate. Changes in interest rates, and LIBOR and the prime rate in particular, can affect our cost of funds under this facility; however, we have had no outstanding borrowings under this facility since the third quarter of 2007.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on such evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this Form 10-Q, our disclosure controls and procedures were not effective because of the material weaknesses disclosed in our Form 10-K for the year ended December 31, 2007.

Disclosure controls and procedures are designed with the objective of ensuring that (i) information required to be disclosed in an issuers reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissions rules and forms; and (ii) information is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

Changes in Internal Controls

Other than the remediation steps discussed below, there were no changes to our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Remediation Steps Subsequent to December 31, 2007

Management is taking the following measures to address the material weaknesses identified in the Form 10-K for the year ended December 31, 2007, and to enhance our internal control over financial reporting. Management is:

·

Re-evaluating the process relating to the recording and recognition of revenue in our late stage segment;

·

Working with internal project budget analysts and operational management to enhance our controls for developing, maintaining and amending percent achieved calculations;

·

Providing additional training, review and management, including project budget analysts oversight, of personnel responsible for the percent achieved calculations;

·

Re-evaluating the design of income tax accounting processes and controls and implement new and improved processes and controls, including the addition of tax personnel;

·

Increasing the level of review and discussion of tax reconciliations and supporting documentation with our outside tax advisors and management; and

·

Formalizing a process for documenting decisions made based upon the review of tax packages or any other supporting information provided.

We anticipate that these remediation actions will represent ongoing improvement measures. While we are taking steps to remediate the material weaknesses which were previously disclosed in the Form 10-K for the year ended December 31, 2007, additional monitoring procedures have been put into place. During 2008, we will continue to reassess the effectiveness of our remediation efforts in connection with managements tests of internal control over financial reporting. The resulting errors from the material weaknesses did not have a material effect on our financial results for the three months ended March 31, 2008.



22





---

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

On March 12, 2007, we received notice that the SEC staff had secured a formal order of private investigation. The formal order relates to revenue recognition, earnings, company operations and related party transactions. We have been cooperating fully with the SEC. In late December 2005, we received an informal request from the SEC for documents relating to the duties, qualifications, compensation and reimbursement of former officers and employees. This request also asked for a copy of the report to Senator Grassley by our independent counsel. In a second request, sent March 28, 2006, the SEC asked for information regarding related parties and transactions, duties and compensation of various employees, internal controls, revenue recognition and other accounting policies and procedures and selected regulatory filings. As part of its investigation, the SEC staff interviewed several former employees on the topics identified in the formal order. On June 11, 2007, we received a subpoena from the SEC for additional accounting documents. We have voluntarily complied with these requests and have provided and expect to continue to provide documents to the SEC as requested.

Beginning in late December 2005, a number of class action lawsuits have been filed in the United States District Court for the Southern District of Florida and the United States District Court for the District of New Jersey alleging that PDGI and certain of its former officers and directors violated federal securities laws, such actions are collectively referred to herein as the Federal Securities Actions. We were served notice of these lawsuits in early January 2006. On June 21, 2006, the Judicial Panel for Multidistrict Litigation transferred all of the Federal Securities Actions for pre-trial proceedings in the District of New Jersey, where they were later consolidated.

On November 1, 2006, the Arkansas Teachers Retirement System, the lead plaintiff in the Federal Securities Actions, filed a consolidated amended class action complaint, also referred to herein as the amended complaint. The amended complaint alleges that we and several of our current and former officers and directors violated Sections 11, 12 (a)(2) and 15 of the Securities Act of 1933, as well as Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The amended complaint claims violations of these federal securities laws through misstatements or omissions regarding: the maximum occupancy at our Miami facility, the Miami facilitys purportedly dangerous and unsafe structure, our clinical practices, purported conflicts of interests involving Independent Review Boards used by us, related-party transactions and some former executives qualifications.

On August 1, 2007, we issued a press release announcing that we had entered into an agreement to settle the Federal Securities Actions on the principal terms set forth in an Agreement to Settle Class Action, referred to herein as the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, the class will receive approximately $28.5 million (less legal fees, administration and other costs). We accrued an estimated liability of $10.4 million during the year ended December 31, 2007, which was not covered by our insurance, associated with the Settlement Agreement and other related litigation. We had the option to elect to pay up to $4.0 million of this amount in common stock, or all in cash. The common stock was to be valued according to the volume weighted average closing price for the 10 trading days leading up to the date the district court enters an order formally approving the Settlement Agreement. On December 3, 2007, the Court preliminarily approved the Settlement Agreement. On December 11, 2007, we made cash payments to the plaintiffs escrow account in the amount of $0.3 million and on January 11, 2008, we made cash payments to the plaintiffs escrow account in the amount of $3.7 million. On March 10, 2008, the Court formally approved the Settlement Agreement and entered Final Judgment. On March 24, 2008, we issued 135,870 shares of common stock to the plaintiffs settlement fund to settle the action, or $4.0 million in common stock, the value of such common stock equal to $29.44 per share which was calculated as set forth above. The common stock and cash have not been disbursed to the class. On April 9, 2008, a Notice of Appeal of the Final Judgment was filed. It is uncertain how long the appeals process will take.

Beginning in late December 2005, a total of five stockholder derivative complaints were filed in the United States District Court for the Southern District of Florida and the United States Court for the District of New Jersey against certain of our current and former officers and directors, as well as PDGI (as a nominal defendant) for alleged violations of state and federal law, including breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets, unjust enrichment, disgorgement under the Sarbanes-Oxley Act of 2002 and violation of Section 14(a) of the Securities Exchange Act of 1934, such actions are referred to herein as the Federal Derivative Actions. We were served notice of these lawsuits in early January 2006. The Federal Derivative Actions allege that the individual defendants misrepresented and engaged in a conspiracy to misrepresent our business condition, prospects and financial results, failed to disclose our allegedly improper and reckless business practices, such as mismanagement of clinical trials and mistreatment of research participants, used our artificially inflated stock to acquire other companies and complete public offerings and engaged in illegal insider trading.



23





---

Beginning in late January 2006, two substantially similar derivative actions were filed in the Florida Circuit Court, also referred to herein as the Florida Circuit Court Derivative Action. On June 21, 2006, the Judicial Panel for Multidistrict Litigation transferred the Federal Derivative Actions pursuant to 28 U.S.C. § 1407 for pre-trial proceedings in the District of New Jersey, where they were later consolidated. Such consolidated action is referred to herein as the Federal Derivative Action.

Following the decision of the Judicial Panel for Multidistrict Litigation and the decision to consolidate all of the Federal Derivative Actions in the District of New Jersey, the Florida Circuit Court entered an order staying those cases pending final resolution of the Federal Derivative Action.

A consolidated amended complaint was filed in the Federal Derivative Action on November 13, 2006. On January 11, 2007, the defendants filed a motion to dismiss that amended complaint. On July 24, 2007, the district court denied the defendants motion to dismiss the Federal Derivative Action. On September 17, 2007, the parties sent the Court a letter informing the Court that the parties have engaged in settlement discussions. The parties have agreed to extend the deadline for all defendants to respond to the operative complaint pending settlement negotiations. As a result of the settlement discussions, we reached a preliminary agreement to settle the Federal Derivative Action. Under the terms of the agreement, the plaintiffs will receive $2.0 million in cash, of which $1.0 million will be covered by our insurance policy. Under the terms of the agreement, we do not admit to any liability by us or any of our current and former directors, officers and employees who were named in the lawsuit.  The agreement has been finalized, but it is not yet signed, and the settlement is subject to court approval and other customary conditions.

If the settlement agreement is not ultimately finalized, the individuals named as defendants in the Federal Derivative Action and the Florida Circuit Court Derivative Action intend to vigorously defend against the lawsuits. As the outcome of these matters is difficult to predict, significant changes in our estimated exposures could occur.

Our attempts to resolve these legal proceedings involve a significant amount of attention from our management, additional cost and uncertainty, and these legal proceedings may result in material damage or penalty awards or settlements, and may have a material and adverse effect on our results of operations, including a reduction in net earnings and a deviation from forecasted net earnings.



Item 1A.

Risk Factors

The risks described below are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. If any of the following risks were to occur, individually or in the aggregate, our business, financial condition, results of operations or cash flows could be materially adversely affected.

Risks Related to Our Business

Our indebtedness may impact our financial condition or results of operations, and the terms of our outstanding indebtedness may limit our activities.

We are currently in default under our Credit Facility, and while we are in negotiations with our lenders to correct this situation, we cannot assure you that we will be able to restore our borrowing capacity to accommodate our business needs. In the event we are able to restore our borrowing capacity, subject to applicable restrictions in our outstanding indebtedness, we may incur additional indebtedness in the future. We do not expect to need to borrow under our Credit Facility in the near future. Our level of indebtedness will have several important effects on our future operations, including, among others:

·

we may be required to use a portion of our cash flow from operations for the payment of principal and interest due on our outstanding indebtedness,

·

our outstanding indebtedness and leverage will increase the impact of negative changes in general economic and industry conditions, as well as competitive pressures, and

·

the level of our outstanding indebtedness may affect our ability to obtain additional financing for working capital, capital expenditures or general corporate purposes.



24





---

General economic conditions, industry cycles and financial, business and other factors affecting our operations may affect our future performance. As a result, these and other factors may affect our ability to make principal and interest payments on our indebtedness. Our business might not continue to generate cash flow at or above current levels. Moreover, if we are required to repatriate foreign earnings in order to pay our debt service, we may incur significant additional income taxes. This may also have the impact of reducing our earnings per share and the amount of net cash we receive. If we cannot generate sufficient cash flow from operations to service our indebtedness, we may, among other things:

·

seek additional financing in the debt or equity markets,

·

seek to refinance or restructure all or a portion of our indebtedness,

·

sell selected assets, or

·

reduce or delay planned capital expenditures.

These measures might not be sufficient to enable us to service our indebtedness. In addition, any financing, refinancing or sale of assets might not be available on economically favorable terms, if at all.

Furthermore, our current Credit Facility contains certain restrictive covenants which will affect, and in many respects significantly limit or prohibit, among other things, our ability to:

·

incur indebtedness,

·

create liens,

·

pay dividends or make other distributions on or redeem or repurchase capital stock,

·

issue capital stock,

·

make capital expenditures, and

·

sell assets.

We may not have sufficient funds to pay the principal return upon conversion or to repurchase our outstanding convertible senior notes under circumstances when we are required to do so as early as August 2009.

Our convertible senior notes are convertible at the option of the holders at any time. The initial conversion rate of the notes is 24.3424 shares of common stock per $1,000 principal amount of the notes. This is equivalent to an initial conversion price of $41.08 per share of common stock. However, the notes provide for what is known as net share settlement upon conversion. This means thatupon conversion of the notes, we will be required to pay up to $1,000 in cash, per $1,000 principal amount of notes, and, if applicable, issue a number of shares of our common stock based upon the conversion value in excess of the principal amount. The conversion value of the notes is based on the volume weighted average price of our common stock for the ten trading-day period commencing the second trading day after we receive notice of conversion. The conversion value must be paid as soon as practicable after it is determined. In addition, holders of the notes may require us to purchase their notes for cash on August 15, 2009, 2014 and 2019, and, under certain circumstances, in the event of a fundamental change as defined in the indenture under which the notes were issued. Further, if a fundamental change occurs prior to August 15, 2009, we will be required to pay a make-whole premium in addition to the repurchase price, which may be payable at our election in cash or shares of our common stock, valued at 97% of the then current market price, or a combination of both.

Finally, if we violate certain covenants contained in the notes, which include a covenant to timely file certain SEC reports, such a violation may be considered an event of default.

We may not have sufficient funds at any such time to make the required payment upon conversion or to purchase the notes, and we may not be able to raise sufficient funds to satisfy our obligations. Due to uncertainties inherent in the capital markets (e.g., availability of capital, fluctuation of interest rates, etc.), we cannot be certain that existing or additional financing will be available to us on acceptable terms, if at all. The financial markets generally, and the credit markets in particular, are and have been experiencing substantial turbulence and volatility, both in the U.S. and in other markets worldwide. Market situations can result in substantial reductions in available loans to a broad spectrum of businesses, increased scrutiny by lenders of the credit-worthiness of borrowers, more restrictive covenants imposed by lenders upon borrowers under credit and similar agreements and, in some cases, increased interest rates under commercial and other loans. Even if we are able to obtain additional debt financing, we may



25





---

incur additional interest expense, which may decrease our earnings, or we may become subject to covenants and other contractual provisions that restrict our operations. Furthermore, the terms of our Credit Facility contain financial covenants or other provisions that could be violated by payment of the required amounts upon conversion or the repurchase of the notes. Our failure to pay the required amounts on conversion of any of the notes when converted or to repurchase any of the notes when we are required to do so would result in an event of default with respect to the notes, which could result in the entire outstanding principal balance and accrued but unpaid interest on all of the notes being accelerated, and could also result in an event of default under our other outstanding indebtedness.

Depending upon the outcome, the inquiry by the SEC can result in our being sued by the SEC and being subject to equitable relief, including payment of a fine and civil monetary penalties and a possible restatement of our prior financial statements.

On March 12, 2007, we received notice that the SEC staff had secured a formal order of private investigation. The formal order relates to revenue recognition, earnings, company operations and related party transactions. Prior to that, in late December 2005, we received an informal request from the SEC for documents relating to the duties, qualifications, compensation and reimbursement of former officers and employees. This request also asked for a copy of the report to Senator Grassley by Independent Counsel. In a second request, sent March 28, 2006, the SEC asked for information regarding related parties and transactions, duties and compensation of various employees, internal controls, revenue recognition and other accounting policies and procedures, and selected regulatory filings. As part of its investigation, the SEC staff interviewed several former employees on the topics identified in the formal order. On June 11, 2007, we received a subpoena from the SEC for additional accounting documents. We have voluntarily complied with these requests and have provided and expect to continue to provide documents to the SEC as requested. We have been cooperating fully with the SEC. However, we cannot assure you that we will be able to successfully resolve these matters with the SEC. If we are not able to resolve these matters, we may be sued by the SEC, subject to equitable relief including payment of a fine and civil monetary penalties and a possible restatement of our prior financial statements, which may have a material adverse affect on our results of operations.

While we have insurance coverage in connection with the settled securities class action and pending derivative action, the settlement for the securities class action suit exceeds our directors and officers, or D&O, liability insurance coverage limits, and there will be limited additional coverage for the derivative actions and associated future legal fees.

We are subject to a number of class actions and derivative actions in federal court which were consolidated in the District of New Jersey. A number of securities class actions and derivative actions have been filed against us. The securities class action alleged that we and certain of our former officers and directors engaged in violations of the anti-fraud provisions of the federal securities laws. The derivative suits are brought on behalf of PharmaNet against certain of our former officers and/or directors alleging, among other things, breaches of fiduciary duty. The complaints in these actions seek, among other things, unspecified damages and costs associated with the litigation. As of December 31, 2006, our $250,000 insurance deductible was reached. On August 1, 2007, we entered into an Agreement to Settle Class Action to settle the securities class action lawsuit. Under the terms of the Agreement to Settle Class Action, which was approved by the court on March 10, 2008 but later appealed on April 9, 2008, our D&O insurance coverage has been exceeded. Since the settlement of the securities class action suit has exhausted our D&O policy limits, we have only limited coverage under our Side A policies for additional legal fees or to cover any adverse judgment in the derivative suit. As such, our future earnings and financial condition could be materially and adversely affected. Additionally, in the event the derivative action continues to be litigated, the attention of our management and other personnel could be diverted.

If we do not continue to generate a large number of new client contracts, or if our clients cancel or defer contracts, our profitability may be adversely affected.

On average, our late stage contracts extend over a period of approximately two and a half years, although some may be of shorter or longer duration. However, all of our contracts are generally cancelable by our clients with little or no notice. A client may cancel or delay existing contracts with us at its discretion. Our inability to generate new contracts on a timely basis could have a material adverse effect on our business, financial condition or results of operations. In addition, since a large portion of our operating costs are relatively fixed, variations in the timing and progress of contracts can materially affect our financial results. The loss or delay of a large project or contract or the loss or delay of multiple smaller contracts could have a material adverse effect on our business, financial condition



26





---

or results of operations. We experience termination, cancellation and delay of contracts by clients from time to time in the ordinary course of business. If client cancellations continue at the rates experienced in our last two fiscal quarters, our future financial results could be negatively impacted.

Our backlog may not be indicative of future results.

Our backlog of $482.9 million as of March 31, 2008, is based on anticipated service revenue from uncompleted projects with clients. Backlog is the amount of revenue that remains to be earned and recognized on written awards, signed contracts and letters of intent. Contracts included in backlog are subject to termination by our clients at any time. In the event that a client cancels a contract, we would be entitled to receive payment for all services performed up to the cancellation date, and subsequent client-authorized services related to terminating the cancelled of the project. The duration of the projects included in our backlog range from a few weeks to many years. We cannot assure you that this backlog is indicative of future results. A number of factors may affect backlog, including:

·

the variable size and duration of the projects,

·

the loss or delay of projects,

·

the change in the scope of work during the course of a project, and

·

the cancellation of such contracts by our clients.

Also, if clients delay projects, the projects will remain in backlog but will not generate revenue at the rate originally expected. Accordingly, historical indications of the relationship of backlog to revenues are not indicative of future results.

We may bear financial risk if we under-price our contracts or overrun cost estimates.

Most of our contracts are fixed-price contracts or fee-for-service contracts. We bear the financial risk if we initially under-price our contracts or otherwise overrun our cost estimates. In addition, contacts with our clients are subject to change orders, which occur when the scope of work performed by us needs to be modified from that originally contemplated by our contract with the clients. This can occur, for example, when there is a change in a key study assumption or parameter or a significant change in timing. Under U.S. generally accepted accounting principles, we cannot recognize additional revenue anticipated from change orders until appropriate documentation is received by us from the client authorizing the change made. However, if we incur additional expense in anticipation of receipt of that documentation, we must recognize the expense as incurred. Further, we may not be successful convincing our clients to approve change orders which change the scope of current contracts. Such under-pricing or significant cost overruns could have a material adverse effect on our business, results of operations, financial condition or cash flows.

We have grown over the last few years and our growth has placed, and is expected to continue to place, significant demands on our infrastructure.

We have grown rapidly, both organically and through acquisitions and our rapid growth has placed, and is expected to continue to place, significant demands on our management and on our accounting, financial, information and other systems. Although we have expanded our management, we must continue to recruit and retain experienced employees capable of providing the necessary support. In addition, we must continue to improve our financial, accounting, information and other systems in order to effectively manage our growth. In particular, our late stage business faces significant competition for clinical trial monitors and other experienced personnel. We also continue to expand our early stage and late stage facilities. As the result of the discontinuation of our Florida operations and our change in senior management in 2006, we have reorganized and are now managing our operations on a more centralized basis from our corporate headquarters in Princeton, New Jersey. We cannot assure you that we will be able to manage our growth and integrate acquired businesses effectively or successfully, or that our financial, accounting, information and other systems will be able to successfully accommodate our growth. Our failure to meet these challenges could materially impair our business.

A significant portion of our growth has come from acquisitions, and we may make more acquisitions in the future as part of our growth strategy. This growth strategy subjects us to numerous risks.

An important aspect of our growth strategy is the pursuit of strategic acquisitions of related businesses that we believe can expand or complement our business. Acquisitions require significant capital resources and can divert



27





---

managements attention from our existing business. Acquisitions also entail an inherent risk that we could become subject to contingent or other liabilities, including liabilities arising from events or conduct predating our acquisition, that were not known to us at the time of acquisition. We may also incur significantly greater expenditures in integrating an acquired business than we had anticipated at the time of the acquisition. Acquisitions may also have unanticipated tax and accounting ramifications. A key element of our acquisition strategy has been to retain management of acquired businesses to operate the acquired business for us. Many of these individuals maintain important contacts with clients of the acquired business. Our inability to retain these individuals could materially impair the value of an acquired business. Our failure to successfully identify and consummate acquisitions or to manage and integrate the acquisitions we make could have a material adverse effect on our business, financial condition or results of operations. We cannot assure you that:

·

we will identify suitable acquisition candidates,

·

we will receive any required consent under our Credit Facility,

·

we can consummate acquisitions on acceptable terms,

·

we can successfully integrate any acquired business into our operations or successfully manage the operations of any acquired business, or

·

we will be able to retain an acquired companys significant client relationships, goodwill and key personnel or otherwise realize the intended benefits of any acquisition.

Our Credit Facility contains certain restrictive covenants that may limit our ability to enter into acquisitions by setting limits on the amount of additional debt that we can incur for financing any acquisitions. The Credit Facility also restricts the terms of equity consideration paid in acquisitions. We are currently in default under our Credit Facility.

We are subject to changes in outsourcing trends and regulatory requirements affecting the branded pharmaceutical, biotechnology, generic drug and medical device industries which could adversely affect our operating results.

Economic factors and industry and regulatory trends that affect our clients also affect our business and operating results. The outsourcing of drug development activities grew substantially during the past decade and we benefited from this growth. If the branded pharmaceutical, biotechnology, generic drug and medical device companies reduce the outsourcing of their clinical research and other drug development projects, our operations could be adversely affected. A continuing negative trend could have an ongoing adverse effect on our business, results of operations or financial condition. Numerous governments have undertaken efforts to control growing healthcare costs through legislation, regulation and voluntary agreements with medical care providers and pharmaceutical companies. Potential regulatory changes under consideration include the mandatory substitution of generic drugs for innovator drugs, relaxation in the scope of regulatory requirements and the introduction of simplified drug approval procedures. If future regulatory cost containment efforts limit the profits which can be derived from new and generic drugs or if regulatory approval standards are relaxed, our clients may reduce the business they outsource to us. We cannot predict the likelihood of any of these events. In addition, consolidation in the pharmaceutical and biotechnology industries can adversely affect us, particularly in circumstances where a client of ours is acquired by another company that does not utilize our services.

If branded pharmaceutical, biotechnology, generic drug or medical device companies reduce their expenditures, our future revenue and profitability may be reduced.

Our business and continued expansion depend on the research and development expenditures of our clients which, in turn, are impacted by their profitability. If these companies want to reduce costs, they may proceed with fewer clinical trials and other drug development. An economic downturn or other factors may cause our clients to decrease their research and development expenditures which could adversely affect our revenues and profitability.

Actions or inspections by regulatory authorities may cause clients not to award future contracts to us or to cancel existing contracts, which may have a material and adverse effect on our results of operations.

We may be subject to continuing inspections of our facilities and documentation in connection with studies we have conducted in support of marketing applications, or routine inspections of our facilities that have yet to be inspected by regulatory authorities. Regulatory authorities can have significant authority over the conduct of clinical



28





---

trials, and they have the power to take regulatory and legal action in response to violations of clinical standards, subject protection and regulatory requirements in the form of civil and criminal fines, injunctions and other measures. If, for example, the FDA obtains an injunction, such action could result in significant obstacles to future operations. Additionally, there is a risk that actions by regulatory authorities, if they result in significant inspectional observations or other measures, could cause clients not to award us future contracts or to cancel existing contracts. Depending upon the amount of revenue lost, the results could have a material and adverse affect on our results of operations.

We might lose business opportunities as a result of healthcare reform.

Numerous governments have undertaken efforts to control healthcare costs through legislation, regulation and voluntary agreements with healthcare providers and drug companies. Healthcare reform could reduce the demand for our services and, as a result, our revenue. In the last several years, the U.S. Congress has reviewed several comprehensive healthcare reform proposals. The proposals are intended to expand healthcare coverage for the uninsured and reduce the growth of total healthcare expenditures. Congress has also considered and may adopt legislation which could have the effect of putting downward pressure on the prices that pharmaceutical and biotechnology companies can charge for prescription drugs. Any such legislation could cause our customers to spend less on research and development. If this were to occur, we could have fewer clinical trials for our business, which could reduce our earnings. Similarly, pending healthcare reform proposals outside the U.S. could negatively impact revenues from foreign operations.

At any given time, one or a limited number of clients may account for a large percentage of our revenues, which means that we could face a greater risk of loss of revenues if we lose a major client.

Historically, a small number of clients has generated a large percentage of our net revenue in any given period. Companies that constitute our largest clients vary from year to year, and our direct revenue from individual clients fluctuates each year. If we lose one or more major clients, or if one or more clients encounter financial difficulties, our business, financial condition or results of operations could be materially adversely affected.

We may incur significant taxes to repatriate funds.

If a significant amount of cash is needed in the U.S. beyond the borrowing capacity of our Credit Facility and we are not able to effectively negotiate revised terms of the Credit Facility or devise effective repatriation strategies, we may need to repatriate funds from foreign subsidiaries in a non-tax-efficient manner, which may require us to pay additional taxes and could have the impact of reducing the amount of net cash available to us and reducing earnings per share. In addition, because of our significant international operations, if we are required to repatriate funds from our foreign operations, we could incur significant tax expense in doing so.

Our operating results can be expected to fluctuate from period to period.

Fluctuating operating results are usually due to the level of new business awards in a particular period and the timing of the initiation, progress or cancellation of significant projects. Even a short acceleration or delay in such projects could have a material effect on our results in a given reporting period. Varying periodic results could adversely affect the price of our common stock if investors react to our reporting operating results which are less favorable than in a prior period or lower than those anticipated by investors or the financial community generally.

If we are required to write off goodwill or other intangible assets, our financial position or results of operations could be adversely affected.

We periodically evaluate goodwill and other intangible assets for impairment. Any future determination requiring the write-off of a significant portion of our goodwill or other intangible assets could adversely affect our results of operations or financial condition.



29





---

Our business is subject to international economic, political and other risks that could negatively affect our results of operations or financial position.

A significant portion of our revenues are derived from countries outside the U.S. and we anticipate that revenues from foreign operations may grow. Accordingly, our business is subject to risks associated with doing business internationally, including:

·

less stable political and economic environments and changes in a specific countrys or regions political or economic conditions,

·

potential negative consequences from changes in tax laws affecting our ability to repatriate profits,

·

unfavorable labor regulations,

·

greater difficulties in managing and staffing foreign operations,

·

the need to ensure compliance with the numerous regulatory and legal requirements applicable to our business in each of these jurisdictions, and to maintain an effective compliance program to ensure compliance,

·

currency fluctuations,

·

changes in trade policies, regulatory requirements and other barriers,

·

civil unrest or other catastrophic events, and

·

longer payment cycles of foreign customers and difficulty collecting receivables in foreign jurisdictions.

These factors are beyond our control. The realization of any of these or other risks associated with operating in foreign countries could have a material adverse effect on our business, results of operations or financial condition.

Our substantial non-U.S. operations expose us to currency risks.

Changes in the exchange rate between the Canadian dollar, Euro, Swiss Franc or other foreign currencies and the U.S. dollar could materially affect the translation of our subsidiaries financial results into U.S. dollars for purposes of reporting our consolidated financial results. We operate in many countries and are subject to exchange rate gains and losses for multiple currencies. We may also be subject to foreign currency transaction risk when our service contracts are denominated in a currency other than the currency in which we incur expenses or earn fees related to such contracts. We have adopted a foreign currency risk hedging policy in an attempt to mitigate this risk. We have also implemented systems and processes to further mitigate this risk; however, we cannot assure you that we will be successful in limiting our risks associated with foreign currency transactions.

We could be adversely affected by tax law changes in Canada or in other foreign jurisdictions.

Our operations in Canada currently benefit from favorable corporate tax arrangements. We receive substantial tax credits in Canada from both the Canadian federal and Quebec provincial governments. Our Canadian operations employ a large number of research and development employees which results in significant expenses related to these services. Due to the nature of these services, the Canadian government subsidizes a portion of these expenses through tax credits that result in a reduced effective tax rate and significant deferred tax assets in the consolidated balance sheets. However, there is no assurance that the credits will be fully realized. Further, any reduction in the availability or amount of these tax credits could have a material adverse effect on profits and cash flows from our Canadian operations. Additionally, a significant portion of our net earnings is generated outside the U.S. where tax rates are generally lower. If applicable foreign tax rates increase, particularly in Switzerland, our consolidated net earnings could be reduced.

Governmental authorities may question our inter-company transfer pricing policies or change their laws in a manner that could increase our effective tax rate or otherwise harm our business.

As a U.S. company doing business in international markets through subsidiaries, we are subject to foreign tax and inter-company pricing laws, including those relating to the flow of funds between the parent and subsidiaries. Regulators in the U.S. and in foreign markets closely monitor our corporate structure and how we effect inter-company fund transfers. If regulators challenge our corporate structure, transfer pricing mechanisms or inter-company transfers, our operations may be negatively impacted and our effective tax rate may increase. Tax rates vary from country to country and if regulators determine that our profits in one jurisdiction should be increased, we



30





---

may not be able to fully utilize all foreign tax credits that are generated, which would increase our effective tax rate. We cannot assure you that we will be in compliance with all applicable customs, exchange control and transfer pricing laws despite our efforts to be aware of and to comply with such laws. Further, if these laws change, we may need to adjust our operating procedures and our business could be adversely affected.

We may lack the resources needed to compete effectively with larger competitors.

There are a large number of drug development services companies ranging in size from very small firms to very large full service, global drug development companies. Intense competition may lead to price pressure or other conditions that could adversely affect our business. Some of our competitors are substantially larger than us and have greater financial, human and other resources. We may lack the operating and financial resources needed to compete effectively.

If we do not continue to develop new assay methods for our analytical applications, or if our current assay methods are incorrect, we may be unable to compete with other entities offering bioanalytical laboratory services.

We must continuously develop assay methods to test drug products in order to meet the needs of our clients and to attract new clients. In order to substantially increase the business of our bioanalytical laboratories, which provide services for branded pharmaceutical, biotechnology and generic drug companies, we must be able to provide bioanalytical solutions for our clients. This requires staying abreast of current regulatory requirements and identifying assay methods and applications that will assist our clients in obtaining approval for their products. If we are not successful in developing new methods and applications, we may lose our current clients or not be able to compete effectively for new clients. Moreover, if our current assay methods are incorrect, we may need to repeat our tests which could have an adverse effect on our operations.

We risk potential liability when conducting clinical trials, which could cost us large amounts of money.

Our clinical trials involve administering drugs to humans in order to determine the effects of the drugs. By doing so, we are subject to the general risks of liability to these persons, which include those relating to:

·

adverse side effects and reactions resulting from administering these drugs to a clinical trial participant,

·

unintended consequences resulting from the procedures or changes in medical practice to which a study participant may be subject as part of a clinical trial,

·

improper administration of these drugs, or

·

potential professional malpractice of our employees or contractors, including physicians.

Our contracts may not have adequate indemnification agreements requiring our clients to indemnify us in the event of adverse consequences to our participants caused by their drugs or participation in their trials. We carry liability insurance, but there is no certainty as to the adequacy or the continued availability at rates acceptable to us of such liability insurance. We could also be held liable for other errors or omissions in connection with our services. For example, we could be held liable for errors or omissions or breach of contract if our laboratories inaccurately report or fail to report lab results. If we do not perform our services to contractual or regulatory standards, the clinical trial process could be adversely affected. Additionally, if clinical trial services such as laboratory analysis do not conform to contractual or regulatory standards, trial participants could be affected. If there is a damage claim not covered by insurance, the indemnification agreement is not enforceable or broad enough or our client is insolvent, any resulting award against us could result in our experiencing a material loss.

We face a risk of liability from our handling and disposal of medical wastes, which could cause us to incur significant costs or otherwise adversely affect our business.

Our clinical trial activities and laboratory services involve the controlled disposal of medical wastes which are considered hazardous materials. Although we may use reputable third parties to dispose of medical waste, we cannot completely eliminate the risk of accidental contamination or injury from these materials. If this occurs, we could be held liable for clean-up costs, damages or significant fines, or face the temporary or permanent shutdown of our operations.

Failure to comply with applicable governmental regulations could harm our operating results and reputation.

We may be subject to regulatory action, which in some jurisdictions includes criminal sanctions, if we fail to comply with applicable laws and regulations. Failure to comply can also result in the termination of ongoing



31





---

research and disqualification of data collected during the clinical trials. This could harm our reputation, our prospects for future work and our operating results. A finding by the FDA or other regulatory agencies that have jurisdiction over the trials we conduct or our operations that we are not in compliance with GLP standards for our laboratories, current GMP standards, where applicable or GCP standards for our clinical facilities or study sites we monitor could materially and adversely affect us. Similarly, a finding by the TPD that we are not in compliance with Canadian GMP, Canadian GCPs or other legislative requirements for clinical trials in Canada, could materially and adversely affect us. In addition to the above U.S. and Canadian laws and regulations, we must comply with the laws of all countries where we do business, including laws governing clinical trials in the jurisdiction where the trials are performed. Failure to comply with applicable requirements could subject us to regulatory risk, liability and potential costs associated with redoing the trials, which could damage our reputation and adversely affect our operating results.

If we lose the services of our key personnel or are unable to attract qualified staff, our business could be adversely affected.

Our success is substantially dependent upon the performance, contributions and expertise of our senior management team, including, among others, our chief executive officer, the executive committee and certain key officers of our subsidiaries. In addition, some members of our senior management team play a significant role in generating new business and retaining existing clients. We also depend on our ability to attract and retain qualified management, professional and operating staff. The loss of the services of any of the members of senior management or any other key executive, or our inability to continue to attract and retain qualified personnel could have a materially adverse effect on our business.

Our business depends on the continued effectiveness and availability of our information technology infrastructure, and failures of this infrastructure could harm our operations.

To remain competitive in our industry, we must employ information technologies that capture, manage and analyze the large streams of data generated during our clinical trials in compliance with applicable regulatory requirements. In addition, because we provide services on a global basis, we rely extensively on technology to allow the concurrent conduct of studies and work-sharing around the world. As with all information technology, our systems are vulnerable to potential damage or interruptions from fires, blackouts, telecommunications failures and other unexpected events, as well as to break-ins, sabotage or intentional acts of vandalism. Given the extensive reliance of our business on technology, any substantial disruption or resulting loss of data that is not avoided or corrected by our backup measures could harm our business and operations.

We are self-insured in the U.S. related to employee healthcare insurance, which exposes us to losses.

We are self-insured for our U.S. employee medical plan. While our medical costs in recent years have generally increased at the same level as the regional average, the mix and age of our workforce could result in higher than anticipated medical claims, resulting in an increase in costs beyond what we have experienced. We have stop loss coverage in place for catastrophic events, but the aggregate impact may have an effect on profitability.

If we are unable to attract suitable investigators and volunteers for our clinical trials, our clinical development business might suffer.

The clinical research studies we operate rely upon the ready accessibility and willing participation of physician investigators and volunteer subjects. Investigators are typically located at hospitals, clinics or other sites and supervise administration of the study drug to patients during the course of a clinical trial. Volunteer subjects generally include people from the communities in which the studies are conducted. Our clinical research development business could be adversely affected if we are unable to attract suitable and willing investigators or clinical study volunteers on a consistent basis.

If we are not able to remediate the material weaknesses relating to our internal controls or if we incur further instances of breakdowns in our internal controls, current and potential stockholders could lose confidence in our financial reporting, which could harm our business and the price of our common stock.

In connection with the internal control audit for the year ended December 31, 2007, our management assessed our internal control over financial reporting and concluded that two material weaknesses existed. Certain studies were not accounted for consistently during the first and third quarters of 2007 as a result of changes in contract estimates, as the method of determining the percent achieved did not follow guidance consistent with Staff Accounting Bulletin No. 104, Revenue Recognition. The resulting errors from this material weakness, which was



32





---

primarily attributable to percent achieved calculations, did not have a material effect on our financial results for the year ended December 31, 2007.

In addition, management determined that the processes and procedures surrounding the preparation and review of the income tax provision and reconciliations did not include adequate review as of December 31, 2007. Specifically, we did not ensure that effective oversight of the work performed by our outside tax advisor was exercised. The resulting errors from this material weakness, which was primarily attributable to accounting for income taxes, did not have a material effect on our financial results for the year ended December 31, 2007. In order to remediate this material weakness, management plans to re-evaluate the design of income tax accounting processes and controls and implement new and improved processes and controls, including the addition of tax personnel.

We cannot assure you that our independent registered public accounting firm will agree with managements assessment that we have begun to remediate the material weaknesses in the manner disclosed in Item 4, or that we will not encounter further instances of breakdowns in our internal control over financial reporting. Public disclosure of these material weaknesses or a failure to promptly complete our remediation effort could cause our common stock price to decrease. Moreover, we believe that any system of internal control can be circumvented by individuals who engage in improper action. In such an event, our results of operations could be distorted. If the improper activity is material, once discovered and publicly disclosed, our common stock price could materially decrease, and we could be required to restate our consolidated financial statements.

The risks and uncertainties associated with discontinued operations could adversely impact our company.

We made the strategic decision in 2006 to discontinue our Florida operations in order to focus on our other businesses. There continue to be risks associated with discontinuing these operations. We may incur costs in addition to those disclosed in the consolidated financial statements. In addition, if we are unable to convince our clients that the problems principally related to our discontinued operations were either not accurately reported or have been rectified, we may lose future revenue and our future results of operations may be materially and adversely affected. The allegations related to our discontinued operations and the repetition of these allegations in the media have harmed our reputation. As a result, clients may decline to give us new contracts for studies to be performed by us unless we can convince them that the allegations, which affected our discontinued operations, have not impacted our ability to provide high quality clinical research in compliance with our clients protocols and all regulatory requirements. Depending upon the impact of the foregoing as well as other issues on our business, the foregoing allegations may have a material adverse affect on our results of operations, including a reduction in our net earnings or a deviation from our forecasted net earnings. Despite the fact that we ceased reporting discontinued operations separately in our financial statements and have successfully completed all studies related to our discontinued operations, we believe the negative effects on our reputation and relationships with clients may continue to pose a risk to our business.

Risks Related to Our Common Stock

We may issue a substantial amount of our common stock which could cause dilution to current investors, put pressure on earnings per share and otherwise adversely affect our stock price.

An element of our growth strategy is to make acquisitions. As part of our acquisition strategy, we may issue additional shares of common stock as consideration for such acquisitions. These issuances could be significant. To the extent that we make acquisitions and issue shares of common stock as consideration, the equity interest of current stockholders will be diluted. Any such issuance will also increase the number of outstanding shares of common stock that will be eligible for resale. Persons receiving shares of our common stock in connection with these acquisitions may be likely to sell their common stock rather than hold their shares for investment, which may impact the price of our common stock. In addition, the potential issuance of additional shares in connection with anticipated acquisitions could lessen demand for our common stock and result in a lower price than might otherwise be obtained. We plan to continue to issue common stock for compensation purposes and in connection with strategic transactions.



33





---

Our stock price can be extremely volatile, and stockholders investments could suffer a decline in value.

The trading price of our common stock has been, and is likely to continue to be, volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:

·

operating performance of our competitors,

·

changes in financial estimates by securities analysts,

·

media articles,

·

loss of a major client or contract,

·

new service offerings introduced or announced by our competitors,

·

changes in market valuations of other similar companies,

·

actual or anticipated variations in quarterly operating results, including changes in our guidance as to forecasted earnings,

·

announcement of significant acquisitions, strategic partnerships, joint ventures or capital commitments,

·

additions or departures of key personnel, and

·

sales of our common stock, including short sales.

As a result, investors could lose all or part of their investment. In addition, the stock market in general experiences price and volume fluctuations that are often unrelated and disproportionate to the operating performance of companies such as us. If any of these risks occur, it could cause our stock price to fall and may expose us to class action lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.

Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult, which could depress our stock price.

We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents currently may make a change in control of us more difficult, even if a change in control would be beneficial to stockholders. Our charter documents provide that the Board of Directors may issue, without a vote of stockholders, one or more series of preferred stock that has more than one vote per share. This could permit the Board to issue preferred stock to investors who support our management and give effective control of our business to management. Additionally, issuance of preferred stock could block an acquisition resulting in both a decrease in the price of our common stock and a decline in interest in the stock, which could make it more difficult for stockholders to sell their shares. This could cause the market price of our common stock to decrease significantly, even if our business is performing well. Our bylaws also limit who may call a special meeting of stockholders and establish advance notice requirements for nomination for election to the Board of Directors or for proposing matters that can be acted upon at stockholder meetings. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, the Board approves the transaction. The Board may use these provisions to prevent changes in our management and control. Also, under applicable Delaware law, the Board may adopt additional anti-takeover measures in the future. In addition, provisions of certain contracts, such as employment agreements with executive officers, may have an anti-takeover effect.

In December 2005, the Board adopted a Shareholder Rights Plan which has the effect of deterring hostile takeovers. This plan also makes it more difficult to replace or remove our current management team in the event our stockholders believe this would be in their best interest or ours.

We may continue to have potential liability owing to our issuances of securities in possible violation of securities laws.

We previously filed a registration statement covering the registration of up to 150,000 shares of our common stock pursuant to our Employee Stock Purchase Plan, or ESPP. As a result of an error in recordkeeping, the amount of shares authorized under the ESPP exceeded the amount of shares registered on Form S-8 by 400,000 shares. We have determined that the offer and sale of the shares and interests in the ESPP above the amount registered were not exempt from registration under the Securities Act, and that such sale by us to our employees should have been



34





---

registered under the Securities Act. Due to our possible violation of securities laws, we may continue to be contingently liable for rescission or damages to our employees during the one-year period following the sale of such shares. As of March 31, 2008, the aggregate purchase price of shares subject to a right of rescission was $2.2 million. We believe that our estimated current potential liability for rescission claims is not material to our financial condition or results of operations. We do not believe that such an obligation is probable so long as our common stock trades at a price above the price at which we would be obligated to repurchase shares. Such probability would increaseif the price of our common stock were to fall below participants acquisition prices for their interests in the ESPP during the one-year period following the sales of unregistered shares. In addition, regulators may pursue actions or impose penalties and fines against us with respect to any potential violations of securities laws.

On April 7, 2008, we filed a Form S-8 registration statement with the SEC to register the 400,000 shares of common stock that had been authorized for issuance by our Board of Directors and approved by our stockholders but not registered. We cannot assure that registering these shares will be successful in limiting our risk associated with the possible violation of securities laws.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

We have an Employee Stock Purchase Plan, also referred to herein as the ESPP, which permits eligible employees, excluding executive officers, to purchase up to 550,000 shares of our common stock. We previously filed a registration statement covering the offering of up to 150,000 shares of our common stock pursuant to our ESPP. As a result of an error in recordkeeping, the amount of shares issued under the ESPP has exceeded the amount of shares registered on Form S-8. We have determined that the offer and sale of the shares and interests in the ESPP above the amount registered were not exempt from registration under the Securities Act, and that such sales should have been registered under the Securities Act. Under the applicable provisions of federal securities laws, plan participants who purchased such unregistered shares of common stock may seek to rescind the transaction within one year following the date of purchase.

Prior to June 30, 2007, we sold 159,065 unregistered shares to plan participants. From July 1, 2007, through March 31, 2008, we sold 97,387 unregistered shares to plan participants in two separate transactions. For the offering period ended June 30, 2007, we sold 56,266 shares at $18.75 per share. For the offering period ended December 31, 2007, we sold 41,121 shares at $27.10 per share. Accordingly, until June 30, 2008, the aggregate purchase price of shares subject to rescission is $2.2 million. After June 30, 2008, and until December 31, 2008, the aggregate purchase price of shares subject to rescission was $1.1 million. We are not obligated to purchase any shares after December 31, 2008. The closing price of our common stock on May 5, 2008, was $14.82 per share.

While we believe that the possibility of rescission of a portion of the ESPP shares may occur, the repurchase of the shares issued on July 1, 2007, and January 1, 2008, is not solely within our control. On April 7, 2008, we filed a Form S-8 registration statement with the SEC to register the 400,000 shares of common stock that had been authorized for issuance by our Board of Directors and approved by our stockholders but not registered.

Item 6.

Exhibits

Exhibit Index



|               |  |                                                                           
|-------------- |  | --------------------------------------------------------------------------
|Exhibit Number |  | Description                                                               
|31.1           |  | Certification of Chief Executive Officer (filed herewith)                 
|31.2           |  | Certification of Chief Financial Officer (filed herewith)                 
|32.1           |  | Section 1350 Certification of Chief Executive Officer (furnished herewith)
|32.2           |  | Section 1350 Certification of Chief Financial Officer (furnished herewith)



35





---



SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf on May 8, 2008, by the undersigned, thereunto duly authorized.

| |                                   |                                                                                                                     
| | --------------------------------- | --------------------------------------------------------------------------------------------------------------------
| | PharmaNet Development Group, Inc.
| |                                   |                                                                                                                     
| |                                   |                                                                                                                     
| | By:                               | /s/ JEFFREY P. MCMULLEN                                                                                             
| |                                   | Jeffrey P. McMullen,                                                                                                
| |                                   | President and Chief Executive Officer
(Principal Executive Officer)                                                 
| |                                   |                                                                                                                     
| | By:                               | /s/ JOHN P. HAMILL                                                                                                  
| |                                   | John P. Hamill,                                                                                                     
| |                                   | Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer )











36